Role of Genetics in the Etiology of Autistic Spectrum Disorder: Towards a Hierarchical Diagnostic Strategy
Cyrille Robert, Laurent Pasquier, David Cohen, Mélanie Fradin, Roberto Canitano, Léna Damaj, Sylvie Odent, Sylvie Tordjman

To cite this version:
Cyrille Robert, Laurent Pasquier, David Cohen, Mélanie Fradin, Roberto Canitano, et al.. Role of Genetics in the Etiology of Autistic Spectrum Disorder: Towards a Hierarchical Diagnostic Strategy. International Journal of Molecular Sciences, MDPI, 2017, 18 (3), pp.618. <10.3390/ijms18030618>. <hal-01504651>

HAL Id: hal-01504651
https://hal.sorbonne-universite.fr/hal-01504651
Submitted on 10 Apr 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution 4.0 International License
Role of Genetics in the Etiology of Autistic Spectrum Disorder: Towards a Hierarchical Diagnostic Strategy

Cyrille Robert 1,2, Laurent Pasquier 2, David Cohen 3, Mélanie Fradin 2, Roberto Canitano 4, Léna Damaj 2, Sylvie Odent 2 and Sylvie Tordjman 1,5,*

1 Pôle Hospitalo-Universitaire de Psychiatrie de l’Enfant et de l’Adolescent (PHUPEA), University of Rennes 1 and Centre Hospitalier Guillaume Régnier, 35200 Rennes, France; robertcyrille@live.fr
2 Service de Génétique Clinique, Centre de Référence Maladies Rares Anomalies du Développement (Centre Labellisé pour les Anomalies du Développement de l’Ouest: CLAD Ouest), Hôpital Sud, Centre Hospitalier Universitaire de Rennes, 35200 Rennes, France; laurent.pasquier@chu-rennes.fr (L.P.); Melanie.FRADIN@chu-rennes.fr (M.F.); Lena.DAMAJ@chu-rennes.fr (L.D.); Sylvie.Odent@chu-rennes.fr (S.O.)
3 Hospital-University Department of Child and Adolescent Psychiatry, Pitié-Salpêtrière Hospital, Paris 6 University, 75013 Paris, France; david.cohen@psl.aphp.fr
4 Division of Child and Adolescent Neuropsychiatry, University Hospital of Siena, 53100 Siena, Italy; r.canitano@ao-siena.toscana.it
5 Laboratory of Psychology of Perception, University Paris Descartes, 75270 Paris, France
* Correspondence: s.tordjman@yahoo.fr; Tel.: +33-6-1538-0748; Fax: +33-2-9964-1807

Academic Editor: Merlin G. Butler
Received: 13 December 2016; Accepted: 20 February 2017; Published: 12 March 2017

Abstract: Progress in epidemiological, molecular and clinical genetics with the development of new techniques has improved knowledge on genetic syndromes associated with autism spectrum disorder (ASD). The objective of this article is to show the diversity of genetic disorders associated with ASD (based on an extensive review of single-gene disorders, copy number variants, and other chromosomal disorders), and consequently to propose a hierarchical diagnostic strategy with a stepwise evaluation, helping general practitioners/pediatricians and child psychiatrists to collaborate with geneticists and neuropediatricians, in order to search for genetic disorders associated with ASD. The first step is a clinical investigation involving: (i) a child psychiatric and psychological evaluation confirming autism diagnosis from different observational sources and assessing autism severity; (ii) a neuropediatric evaluation examining neurological symptoms and developmental milestones; and (iii) a genetic evaluation searching for dysmorphic features and malformations. The second step involves laboratory and if necessary neuroimaging and EEG studies oriented by clinical results based on clinical genetic and neuropediatric examinations. The identification of genetic disorders associated with ASD has practical implications for diagnostic strategies, early detection or prevention of co-morbidity, specific treatment and follow up, and genetic counseling.

Keywords: autism; genetic disorders; hierarchical diagnostic strategy; child psychiatric and psychological assessment; clinical genetics; neuropediatric evaluation

1. Introduction

Autism Spectrum Disorder (ASD) is considered as a neurodevelopmental disorder defined in the DSM-5 (the Diagnostic and Statistical Manual of Mental Disorders 5th ed.) [1], the most recent diagnostic classification of mental disorders, by social communication deficits associated with repetitive/stereotyped behaviors or interests with early onset (referenced in the DSM-5 as symptoms present at early developmental period and evident in early childhood). According to the historian Normand J. Carrey, the first description of autism can be traced to Itard in his 1828 report on “mutism
produced by a lesion of intellectual functions” [2]. In 1943, Leo Kanner [3], American psychiatrist with Austrian origins, borrowed the term *autism* from the Swiss psychiatrist Eugen Bleuler to define a specific syndrome observed in 11 children (the term “autism”, derived from the Greek autos which means “oneself”, was used for the first time by Eugen Bleuler in 1911 [4] to describe social withdrawal in adult patients with schizophrenia). The Kanner syndrome was characterized by its early onset (from the first year of life) and symptomatology (social withdrawal, sameness, language impairment, stereotyped motor behaviors, and intellectual disability). It is noteworthy that Kanner did not describe autism in individuals with severe intellectual disability and known brain disorders. The same year, the Austrian psychiatrist Hans Asperger [5] distinguished “personalities with autistic tendencies” which differed from the children that Kanner had described, due to the expression of exceptional isolated talents and conserved linguistic abilities. Currently, autism is viewed as an epistatic and multifactorial disorder involving genetic factors and environmental factors (prenatal, neonatal and/or postnatal environmental factors such as gestational diabetes, neonatal hypoxia conditions, exposure to air pollution, parental immigration or sensory/social deficits; for a review, see Tordjman et al., 2014 [6]).

Several literature reviews underline the important role of genetics in the etiology of autism [7–9]. The data come from family and twin studies. Indeed, the concordance rate among monozygotic twins is high (60%–90%) compared to the concordance rate among dizygotic twins (0%–30%) [10,11]. Technological advances in epidemiological and molecular genetics have led recently to new findings in the field of the genetics of neuropsychiatric disorders. These new findings concern also the domain of the genetics of autism and have increased the state of current knowledge on the genetic disorders associated with ASD. Identified genetic causes of ASD can be classified as the cytogenetically visible chromosomal abnormalities, copy number variants (CNVs) (i.e., variations in the number of copies of one segment of DNA, including deletions and duplications), and single-gene disorders [12]. CNVs can have different sizes (small to large deletions or duplications) and therefore concern a variable number of genes according to their size. The number of known genetic disorders associated with ASD has increased with the use of array Comparative Genomic Hybridization (aCGH), also called chromosomal microarrays (CMAs) or high-resolution molecular karyotype, which is one of the most molecular cytogenetic methods used by geneticists. The accuracy of aCGH is 10 to 100 times higher than low-resolution karyotype accuracy and allows detection of small CNVs. Unfortunately, this method does not detect certain genetic anomalies such as balanced chromosome rearrangements (which are rarely involved in developmental disorders) or CNVs present in less than 10% to 20% of cells (somatic mosaicism). CNVs are usually considered to be rare variants but recent techniques have shown that they may be in fact more frequent than expected [13]. In practice, after CNV detection, the geneticist needs to determine the contribution of this variation to the patient’s disorder. Most of the time, parental CNVs are also analyzed for family segregation. Among genetic causes of ASD, besides single specific genetic factors, cumulative effects of Single Nucleotide Variants (SNVs: common small variations in the DNA sequence occurring within a population) also have to be taken into consideration. Single-nucleotide polymorphism (SNP) is the term usually used for SNVs occurring in more than 1% of the general population. In the next few years, it will be probably possible to improve the identification and interpretation of SNPs in ASD using new techniques of High Throughput Sequencing, such as targeted sequencing on known genes (gene panel) or Whole Exome/Genome Sequencing. Finally, it should be highlighted that a genetic model of ASD (including cumulative genetic variance) does not exclude the role of environment (including cumulative environmental variance). It is noteworthy that heritability ($h^2$) is defined as $h^2 = GV/(GV + EV)$ where GV is the cumulative genetic variance and EV, the environmental variance [14].

Many susceptibility genes and cytogenetic abnormalities have been reported in ASD and concern almost every chromosome (for a review, see Miles, 2011; available online: http://projects.tcag.ca/autism/) [15]. How can we explain such genetic diversity associated with similar autism cognitive-behavioral phenotypes? Given the current state of knowledge, we can state the hypothesis
that the majority of ASD-related genes are involved in brain development and functioning (such as synapse formation and functioning, brain metabolism, chromatin remodeling) [16].

Several studies have reported associations between genetic contribution (such as unbalanced chromosome abnormalities, in particular large chromosomal abnormalities), dysmorphic features and low cognitive functioning [17–19]. Indeed, large chromosomal abnormalities are more often found in children with dysmorphic features, whereas small CNVs and de novo SNPs are more often found in individuals without dysmorphic features. The concept of “syndromic autism” or “complex autism” (autism associated with genetic disorders/genetic syndromes) which qualifies individuals with at least one dysmorphic feature/malformation or severe intellectual disability, is opposed to the concept of “non-syndromic autism” or “simplex”/“pure”/idiopathic autism (isolated autism) which qualifies individuals with moderate intellectual disability to normal cognitive functioning and no other associated signs or symptoms (except the presence of seizures) [19,20]. The prevalence of epilepsy in ASD varies from 5% to 40% (compared to 0.5% to 1% in the general population) according to different variables, including syndromic vs. non-syndromic autism (higher rates of epilepsy are observed in syndromic autism compared to non-syndromic autism) [21–24] and the age of the population (the rate of seizures varies with age and increases especially during the prepubertal period). It is noteworthy that genome-wide association and genetic analyses such as aCGH have revealed hundreds of previously unknown rare mutations and CNVs linked to non-syndromic autism. Some authors [12,19] suggest that syndromic autism (SA), compared to non-syndromic autism (NSA), is associated with a poorer prognosis, a lower male-to-female sex ratio (SA: 3/1; NSA: 6/1), and a lower sibling recurrence risk (SA: 4%–6%; NSA: up to 35%) as well as a lower risk for family history of autism (SA: up to 9%; NSA: up to 20%) given that SA would be more related to accidental mutations than NSA. Similarly, the concept of syndromic intellectual disability (intellectual disability associated with dysmorphism and medical or behavioral signs and symptoms) is widely used as opposed to non-syndromic intellectual disability (intellectual disability without other abnormalities). Intellectual disability and autism spectrum disorder share other similarities given that they are both genetically heterogeneous, and a significant number of genes have been associated with both conditions. It is noteworthy that the concept of non-syndromic autism or non-syndromic intellectual disability depends on technological progress and current state of knowledge. We can foresee, as underlined by Tordjman et al. [25], that individuals with currently and apparently “non-syndromic autism” could become a few years later individuals with “syndromic autism”, if new genetic disorders are identified, allowing a better understanding and more efficient identification of discrete clinical symptoms as minor physical anomalies, malformations and associated biological anomalies. For example, individuals with Smith–Magenis syndrome can show in early childhood ASD associated with subtle minor facial dysmorphic features (these discrete dysmorphic features become more evident later), mild or moderate intellectual disability, disrupted sleep patterns and repetitive self-hugging characteristic of this syndrome. The molecular discovery of Smith–Magenis syndrome is relatively recent (1982) and allowed to better know the characteristic behavioral phenotype with physical anomalies of Smith–Magenis syndrome (including short stature and scoliosis, not enough specific to help alone to identify the genetic syndrome), orienting towards the search for certain dysmorphic features and the possible identification of this genetic disorder. Thus, some children with Smith–Magenis syndrome could be considered in early childhood, especially before the discovery of Smith–Magenis syndrome in 1982, as individuals with apparently “non-syndromic autism” (they are more viewed as individuals with syndromic autism over their developmental trajectory). Therefore, taking into account this bias, it would be better to consider autism as a behavioral syndrome related either to known genetic disorders or to currently unknown causes.

The objective of this article is to show the diversity of the genetic disorders associated with ASD (including single-gene disorders, CNVs and other chromosomal disorders), and consequently to propose a hierarchical diagnostic strategy with a stepwise evaluation, helping
general practitioners/pediatricians and child psychiatrists to collaborate with geneticists and neuropediatricians, in order to search for genetic disorders associated with ASD.

2. Known Genetic Syndromes Associated with Autism Spectrum Disorder

We chose to limit the review of literature to genetic disorders presented in Table 1. Table 1 includes one part on chromosomal disorders and another part on single-gene disorders. The present descriptions focus on autistic traits encountered in each genetic disorder and other symptoms that may be helpful for the diagnosis. Table 1 summarizes these clinical data and indicates the estimated frequency of each genetic disorder in autism and the frequency of autistic traits in each genetic disorder (when available). This table does not present an exhaustive list of genetic disorders associated with ASD. Furthermore, Table 1 includes only genetic syndromes involving a single-gene disorder or a chromosomal rearrangement, and therefore does not include polygenic causes and possible genetic disorders only related to epigenetic mechanisms. It is noteworthy that some studies suggest that the genetic background might play an important role in many ASD individuals, with in particular cumulative genetic effects related to the load of common risk variants [16].
Table 1. Main genetic disorders associated with autistic syndrome.

| Genetic Disorder [References] | Estimated Rate (%) of the Disorder in Autism | Estimated Rate (%) of Autism in the Disorder | Degree of Intellectual Disability (ID) | Possible Autistic Behaviors | Other Possible Behaviors | Other Possible Symptoms |
|-------------------------------|---------------------------------------------|---------------------------------------------|--------------------------------------|----------------------------|-------------------------|------------------------|
| Chromosomal Disorders        |                                             |                                             |                                      |                            |                         |                        |
| Maternal * 15q11–q13 duplication [26–38] | 1–2                                        | 80–100                                     | Severe                               | Severe autistic syndrome with severe expressive language impairment | Hyperactivity and aggression | Seizures (75%), hypotonia, genitor/urinary abnormalities |
| Angelman syndrome * (maternal 15q11-q13 deletion, paternal uniparental disomy, mutations of UBE3A that encodes an ubiquitin E3 ligase) [35,39–48] | 1                                           | 48–80                                      | Severe                               | No language, stereotypies, sameness | Attention Deficit with Hyperactivity Disorder (ADHD), paroxysmal laughter, tantrums | Facial dysmorphosis, microcephaly, seizures (>1 year), ataxia and walking disturbance |
| Prader–Willi syndrome * (maternal uniparental disomy at 15q11-q13, paternal deletions) [35,49–58] Paternal 15q11-q13 duplication (only few cases reported to be associated with autism): behavioral phenotype similar to Prader–Willi syndrome [58–60] | Not Available (NA)                         | 19–37                                      | Mild to moderate                     | Motor and verbal stereotypies, rituals | Hyperphagia, obsessive-compulsive traits, temper tantrums | Obesity, growth delay and hypogonadism, facial dysmorphism, Hypotonia |
| Phelan–McDermid * syndrome (Inherited, de novo deletions at 22q13.3 leading to loss of SHANK 3) 22q13.3 duplication [20,61–70] | NA                                         | 75–84                                      | Severe                               | Variable autistic syndrome with social communication impairments, including delayed or absent verbal language | Global developmental delay, ataxia in adolescence and adulthood | Dysmorphic features, hypotonia, gait disturbance, recurring upper respiratory tract infections, gastrointestinal reflux and seizures |
| 16p11.2 duplication 16p11.2 deletion [71–77] | 1                                           | 33                                         | Severe                               | Severe autistic syndrome with speech impairment | Gross and fine coordination problems, SCH (Schizophrenia), anxiety, ADHD | Hypotonia (Multiple congenital anomalies are possible with more distal region) |
| Inverted duplication/deletion 8p21–22 [78,79] | NA                                         | 30–57                                      | Variable                             | Mild to moderate autistic syndrome with absent or delayed verbal language | ADHD | Minor facial dysmorphism, hypotonia, agenesis of the corpus callosum, possible heart defect |
| Genetic disorder [References] | Estimated rate (%) of the disorder in autism | Estimated rate (%) of autism in the disorder | Degree of intellectual disability (ID) | Autistic behaviors | Other behaviors | Other symptoms |
| Down syndrome * (trisomy 21) [80–84] | 2                                           | 5–10                                       | Variable but usually severe when autism | Severe autistic syndrome | - | Facial dysmorphism, heart and intestine malformations |
| Genetic Disorder [References] | Estimated Rate (%) of the Disorder in Autism | Estimated Rate (%) of Autism in the Disorder | Degree of Intellectual Disability (ID) | Possible Autistic Behaviors | Other Possible Behaviors | Other Possible Symptoms |
|-------------------------------|---------------------------------------------|----------------------------------------------|-------------------------------------|-----------------------------|----------------------------|----------------------------|
| Smith-Magenis syndrome (17p11.2 deletion) [85–88] | <1 | 80–100 | Variable | Self-injurious and stereotyped behaviors, sameness | Tantrums, possible social contact, sleep disturbance | Facial dysmorphism, peripheral neuropathy, hypotonia |
| Potocki–Lupski syndrome (17p11.2 duplication) [89] | NA | 50–100 | Normal to moderate | Decreased eye contact, motor maniérisms or posturing, sensory hypersensitivity or preoccupation, repetitive behaviors or interests, lack of appropriate functional or symbolic play and lack of joint attention | Developmental delay, language impairment, and cognitive impairment | Hypotonia, poor feeding and failure to thrive in infancy, oral-pharyngeal dysphagia, obstructive and central sleep apnea, structural cardiovascular abnormalities, electroencephalography (EEG), abnormalities, and hypermetropia |
| 2q37 deletion [90–94] | <1 | 25–35 | Mild to moderate | Severe communication impairment, stenotypes | Hypotonia, hyperactivity, Obsessive-Compulsive Disorder (OCD), aggression, sleep disturbance | Facial dysmorphism, microcephaly, growth delay/short stature, intestine and heart malformations, seizure |
| 22q11.21 duplication and 22q11 deletion (DiGeorge/Velo-cardio-facial syndrome) [95–100] | NA | <10 | Normal to severe ID | Autistic syndrome, Pervasive Developmental Disorder-Not Otherwise Specified PDD-NOS (ICD-10 criteria) | Learning disability, anxiety, ADHD, oppositional-defiant disorder, OCD, motor impairment | Facial dysmorphism, microcephaly, growth delay/short stature, craniofacial abnormalities/cleft palate, heart defect, hypotonia |
| 1q21.1 Copy-Number Variation (CNV) (1q21.1 deletion/duplication) [101–104] | NA | <30 | Normal to mild ID | Autistic syndrome, PDD-NOS (ICD-10 criteria) | Developmental delay, learning disability, anxiety, ADHD, aggression, SCZ and hallucination | Microcephaly (deletion) Macrocephaly (duplication) |
| Williams-Beuren syndrome * (7q11.23 deletion) and Reciprocal 7q11.23 duplication syndrome [105–117] | <1 | <10 | Mild to moderate | Autistic syndrome | Overfriendliness, over talkativeness, visual spatial deficit, hyperacusis, feeding and sleep problems | Facial dysmorphism, short stature, heart and endocrine malformations, hypercalcemia |
| Turner syndrome * (most common monosomy For X chromosome) [37,118,119] | NA | 3 | Usually normal IQ | Females monosomic for the maternal chromosome X score significantly worse on social adjustment and verbal skills | - | Short stature, skeletal abnormalities, absence of ovarian function, webbed neck, lymphedema in hands and feet, heart defects and kidney problems |
Table 1. Cont.

| Genetic Disorder [References] | Estimated Rate (%) of the Disorder in Autism | Estimated Rate (%) of Autism in the Disorder | Degree of Intellectual Disability (ID) | Possible Autistic Behaviors | Other Possible Behaviors | Other Possible Symptoms |
|--------------------------------|---------------------------------------------|---------------------------------------------|--------------------------------------|----------------------------|--------------------------|------------------------|
| Beckwith-Wiedemann * (abnormal expression of imprinted genes on chromosome 11p15.5 such as IGF2 and/or CDKN1C) [120–123] | NA | 6.8 (replication needed) | Usually normal IQ | Autistic syndrome | - | Pre- and postnatal overgrowth (hemihyperplasia, macroglossia, visceromegaly) and increased risk of embryonal tumors |
| Isodicentric chromosome 15 or duplication/inversion 15q11 [124,125] | NA | NA | Moderate to severe | Autistic behavior | Developmental delay and intellectual deficit, epilepsy | Early central hypotonia |
| Ito hypomelanosis [126,127] | NA | NA | Inconstant | Asperger syndrome (high functioning autism) or atypical autism | Psychomotor delay and cognitive deficit | hypopigmented skin lesions along the Blaschko lines, motor delay, seizures, macrocephaly or macrocephaly, hypotonia, ophthalmological abnormalities |
| CHARGE syndrome * (CHD7, 8q21.1) [128–133] | <1 | 15–50 | Variable but often normal IQ | Variable autistic syndrome | Hyperactivity, obsessive-compulsive traits, tic disorders | Coloboma of the eye, Heart defects, Atresia of the nasal choane, Retardation of growth and/or development, Genital/urinary abnormalities, Ear abnormalities/deafness |
| Tuberous sclerosis (TSC1, 9q34) (TSC2, 16p13.3) [134–136] | 1–4 | 25–60 | Variable | Severe autistic syndrome | Learning disorder | Ectodermal anomalies, renal lesions, seizures |
| PTEN macrocephaly syndromes (PTEN, 10q23.31) [137–142] | 4 in ASD with macro-cephaly | NA | Severe | Autistic syndrome and language delay | = | Progressive macrocephaly, developmental delay, macrosomy, tumors in adulthood |
| Rett’s syndrome * (MECP2, Xq28) [117,143–149] | <1 in female | 61–100 | Severe | Stereotyped hand movements, absence of language, loss of social engagement | Stagnation stage (6–18 months) in girls, then regression stage (12–36 months), pseudostationary t stage (2–10 years), 1 and late motor t deterioration (>10 years) | Head growth deceleration, progressive motor neuron (gait and truncal apraxia, ataxia, decreasing mobility) and respiratory (hyperventilation, breath holding, apnea) symptoms |
| San Filippo syndrome # (SGSH, 17q25.3) [150–153] | 1 replication needed | 80–100 | Severe | Language impairment, autistic withdrawal, stereotyped behaviors impulsivity, inappropriate affects | Progressive loss of acquisitions | Motor regression, hepatomegaly |
| Genetic Disorder [References] | Estimated Rate (%) of the Disorder in Autism | Estimated Rate (%) of Autism in the Disorder | Degree of Intellectual Disability (ID) | Possible Autistic Behaviors | Other Possible Behaviors | Other Possible Symptoms |
|-------------------------------|---------------------------------------------|---------------------------------------------|--------------------------------------|---------------------------|-------------------------|------------------------|
| Cerebral folate deficiency # (FOLR1, 11q13.4) [154–157] | NA | NA | Variable | Autistic syndrome including especially social interaction and language impairment | Irritability, movement (such as tremors) and gait disturbances with ataxia, sleep problems | Psychomotor regression, epilepsy, developmental delay, deceleration of head growth, dystonia/hypotonia, visual and hearing deficit. |
| Smith–Lemli–Opitz syndrome # (DHCR7, 1q12-13) [158–163] | NA | 50 | Variable | Self-injurious behaviors, stereotypies ("opisthokinesis") language impairment | Sensory hyper-reactivity, irritability, sleep disturbance | Facial dysmorphism, cleft palate, congenital heart disease, hypospadias, 2–3 toe syndactyly |
| Phenylketonuria # (BAH, 12q22-q24.1) [20,164,165] | NA | NA | Severe | Self-injurious behavior, lack of social responsiveness | Temper tantrums, hyperactivity | Eczema, hypertonia, seizures, hypo-pigmentation |
| Adenylosuccinate lyase deficiency # (ASL, 22q13.1-13.2) [166–170] | <1 | 80–100 | Variable | Severe autistic syndrome | - | Seizures |
| Creatine deficiency syndrome # (GAMT, 19p13.3) (CRTR, Xq28) [171–174] | <1 | 80–100 | Severe | Severe autistic syndrome with poor language | - | Seizures, hypotonia |
| SHANK 3 (22q13.3) [175–177] | <1 | NA | NA | Severe autistic syndrome with no language | - | - |
| Neurexin family: Neurexin 1 (NRX1, 2p16.3) [178–182] | 1 | NA | Variable | Autistic syndrome | Hyperactivity, depression, learning disability, but also normal behavior | Seizures, hypotonia, facial dysmorphism? |
| Contactin Associated Protein-like 2 (CNTNAP2, 7q35) [183–185] | NA | NA | Variable | Autistic syndrome including verbal language impairment | - | Seizures |
| Contactin 4 (CNTN4, 3p26.2–3p26.3) [186–189] | <1 | NA | Variable | Autistic syndrome, PDD-NOS (ICD-10 criteria) Visual spatial impairment, regression | Facial dysmorphism, developmental delay, hypotonia, ptosis. |
| Cell adhesion molecule-1 (CADMI, 11q22.3–23.2) [190–192] | NA | NA | NA | Autistic syndrome with especially social communication impairment including verbal language deficit | - | - |
| Protocadherin 10 (PCDH10, 4q28) [193] | <1 | NA | NA | Autistic syndrome | - | - |
| Neuroligin family: Neuroligin 3 (NLG3, Xq13) | <1 | NA | Variable | Severe autistic syndrome, PDD-NOS (ICD-10 criteria) Regression | Tic | - |
| Neuroligin 4 (NLG4, Xq22.33) [194–196] |
Table 1. Cont.

| Genetic Disorder [References] | Estimated Rate (%) of the Disorder in Autism | Estimated Rate (%) of Autism in the Disorder | Degree of Intellectual Disability (ID) | Possible Autistic Behaviors | Other Possible Behaviors | Other Possible Symptoms |
|-------------------------------|---------------------------------------------|---------------------------------------------|-------------------------------------|---------------------------|------------------------|------------------------|
| Fragile X* (FMR1, Xq27.3) [191,196–222] | 0–8 | 0–33 | Variable | Poor eye contact, social anxiety, language deficit and stereotypes | Hyperactivity with attention deficit, sensory hyper-reactivity | Facial dysmorphism, macro-orchidism |
| Neurofibromatosis type 1 [109,223–225] | NA | 21–40 | inconstant | Restrictive/repetitive behaviors and severe social-communicative impairments | Cognitive deficits and learning difficulties | Cafe-au-lait spots, iris Lisch nodules, axillary and inguinal freckling, multiple neurofibromas |
| Sotos syndrome [226,227] | NA | 70 (replication needed) | Mild to severe | Self-injurious behavior, physical aggression, and destruction | - | Facial dysmorphism, overgrowth of the body in early life with macrocephaly |
| Aarskog syndrome [228,229] | NA | NA | - | Variable autistic syndrome | Learning and behavioral disabilities | Facial dysmorphism, severe growth delay, abnormal hands and feet, and constant brachymetacarpia of the first metacarpus, various other malformations (heart, kidney, etc.) |
| Cornelia de Lange syndrome [117,230,231] | NA | 43 (replication needed) | Variable | Self-injury, excessive repetitive behaviors and expressive language deficits | Psychomotor delay, language acquisition difficulties | Facial dysmorphism, abnormal respiratory pattern, nystagmus, hypotonia, ataxia, and delay in achieving motor milestones |
| Joubert syndrome [232] | NA | <40 | severe intellectual deficit to normal intelligence | Autistic syndrome | - | Facial dysmorphism, abnormal respiratory pattern, nystagmus, hypotonia, ataxia, and delay in achieving motor milestones |
| Cohen syndrome [117,233–235] | NA | 54 (replication needed) | variable | Atypical autism | Often sociable with a cheerful disposition, learning and behavioral problems | Microcephaly, facial dysmorphism, hypotonia, myopia, retinal dystrophy, neutropenia and truncal obesity |
| Lujan-Fryns syndrome [236] | NA | NA | Mild to moderate | Autistic-like disorder | Behavioral problems, emotional instability, hyperactivity and shyness, schizophrenia | Tall, marfanoid stature, facial dysmorphism, hypernasal voice and generalized hypotonia |
| Noonan syndrome [237–239] | NA | 15 (replication needed) | Mild | ASD | Poor feeding in infancy | Short stature, facial dysmorphism and congenital heart defects |
| Moebius syndrome [128,240,241] | NA | 0–45 | Inconstant, mild | ASD | Delayed walk development | Oculofacial paralysis, strabismus |
| Helsmoortel-Van der Aa syndrome (ADNP-related ID/ASD) [242] | 0.17 | 100 | Mild to severe | ASD, behavioral problems, sleep disturbance | Delayed developmental milestones (walking between 19 months and 4.5 years, and speech ranging from sentences to no words) | Facial dysmorphism, hypotonia, seizures, feeding difficulties, visual problems (hypermetropia, strabismus, cortical visual impairment), and cardiac defects |
| Timothy syndrome (CACNA1C) [243] | NA | 50–70 (replication needed) | Inconstant, mild to severe | ASD | Language, motor, and generalized cognitive impairment | Facial dysmorphism, rate-corrected QT (Qc) interval >480 ms, unilateral or bilateral cutaneous syndactyly, heart defects, seizures |

Adapted from Tordjman et al. [25]. * These genetic disorders are metabolic disorders (the list is not exhaustive). * The asterisk indicates the existence of epigenetic mechanisms observed in these genetic disorders (the list is not exhaustive).
Interestingly, as underlined by Abrahams and Geschwind [7], the descriptive analysis of Table 1 indicates that each of the many known genes or genomic regions associated with ASD, taken separately, accounts usually and on average for less than 2% of autism cases, suggesting high genetic heterogeneity (the maximum average rate is 5% and concerns the Fragile X syndrome). However, taken all together, these single genetic impairments account at least for 10%–25% of ASD individuals [244] and even 35%–40% in more recent studies [245].

3. Recommended Investigations for the Identification of Genetic Disorders Associated with ASD

Facing such a diversity of genetic disorders associated with ASD (see Table 1), it seems important to clarify, as best as possible with regard to the current state of knowledge, the diagnostic steps towards identification of these genetic disorders. A hierarchical diagnostic strategy with a stepwise evaluation towards identification of genetic disorders associated with autism is proposed and developed in Figure 1.

As it appears in Table 1, the severity of the autistic syndrome is an important variable to take into consideration in the search for genetic disorders associated with ASD. Therefore, the preliminary step in the hierarchical diagnostic strategy is to confirm autism diagnosis and assess autism severity. Furthermore, based on the genetic syndromes listed in Table 1, certain variables are of particular interest such as dysmorphic features, malformations, epilepsy and intellectual disability. It indicates clearly that clinical investigation of behavioral phenotype of autism for identification of genetic disorders associated with ASD requires clinical genetic examination, neuropediatric examination and psychological assessment. In this section, we propose a hierarchal diagnostic strategy with focused investigations for the identification of genetic disorders associated with ASD, based on the history of the individual (including family history and developmental trajectory) and the clinical neurologic and genetic evaluation, but also on up-to-date knowledge and new technology. The first step of the hierarchal diagnostic strategy is a clinical investigation involving: (i) a child psychiatrist’s and psychologist’s evaluation to confirm autism diagnosis using different observational sources (including an extensive parental interview facilitating the study of family history) and assess autism severity (including behavioral and cognitive assessments); (ii) a neuropediatrician’s evaluation to examine neurological symptoms/signs and developmental milestones; and (iii) a geneticist’s evaluation to search for dysmorphic features and malformations based on a clinical physical examination. This clinical step is followed by a second step involving laboratory and if necessary neuroimaging or EEG studies oriented by clinical results based on clinical genetic and neuropediatric examinations. These two steps are described below.

3.1. First Step: Clinical Investigation

3.1.1. Autism Diagnosis Using Different Observational Sources and Autism Severity Assessment (Child Psychiatric and Psychological Evaluation)

   The preliminary step requires confirming the diagnosis of autism and assessing the severity of autistic behavioral impairments with validated tools used by trained professionals in different observational situations, such as the Autism Diagnostic Interview-Revised [246] (the ADI-R scale is a parental interview) and the Autism Diagnostic Observation Schedule [247] (the ADOS scale allows a direct observation of the individual through a standardized play situation). The psychiatric appreciation of ICD-10 (International Classification of Diseases, World Health Organization, Geneve, Switzerland, 1993) and DSM-5 (American Psychiatric Association, Washington, D.C., United States, 2013) diagnostic criteria of autism is also necessary and provides a clinical psychiatric judgment. This approach, combining information from multiple sources based on the clinical psychiatric judgment and the administration of the ADI-R completed by the ADOS improves the confidence in the diagnosis of ASD [248]. Interestingly, the ADI-R scale is validated to assess current behavior but also behavior during the 4–5 years old period (the ADI-R algorithm is based on the 4–5 years old period of life which
is supposed to correspond to the most severe period of autistic impairments), allowing to see the evolution between these two periods of life. It happens more frequently than expected that children who fulfill the diagnostic criteria for ASD based on the ADI-R algorithm (parental interview for the 4–5 years old period) do not meet the full diagnostic criteria for ASD based on the ADOS algorithm (direct observation of the child for the current period).

The ADI-R scale is the most common assessment used to conduct an extensive semi-structured parental interview searching for medical and psychiatric family history. This clinical interview should be conducted with empathy and allow a three-generation family tree to be constructed, showing, in particular, family psychiatric history (such as, for example, schizophrenia, depression or bipolar disorder) and ASD behaviors (including delayed language development) within the family (mother’s and father’s sides). The construction of the pedigree can be very helpful to get specific hypotheses of genetic disorders associated with autism. More generally, higher rates of CNVs are observed in ASD individuals with a family history of psychiatric disorders or developmental disabilities, highlighting the importance to study family history [249]. It is noteworthy that family history is also investigated and analyzed by the neuropediatrician and the geneticist during their evaluation.

Furthermore, the clinician should indicate in the family tree the existence of consanguineous mating, family malformations, deceased infants and spontaneous abortions occurring in the mother but also in relatives (repeated spontaneous abortions are in favor of chromosomal rearrangement [20,250,251]). It is necessary to specify the trimester of pregnancy when spontaneous abortions occurred given that repeated miscarriages at the first trimester of pregnancy are more specifically in favor of genetic anomalies. Reproductive stoppage is rarely evoked but should be investigated because reproductive curtailment following the birth of a child with ASD has been reported [252]. In addition, the birth order of the child with autism has to be noted in the family tree given that a decrease of ASD in later siblings has been observed [253]. The maternal and paternal ages at the time of procreation should be also systematically noted. Indeed, several studies suggest that advanced parental age, in particular for the father, is a risk factor for ASD [254], but there are some discrepancies in the results [253]. Although advanced parental age may be a risk factor, it orients towards genetic testing but does not lead to definitive conclusions.

Finally, a psychological evaluation is necessary in this hierarchical diagnostic strategy to assess the level of cognitive functioning given that intellectual disability and its severity are associated, as indicated previously, with a risk for several genetic disorders in ASD individuals (see Table 1). In addition, the level of cognitive functioning should be taken into consideration and therefore assessed given that severe intellectual disability can introduce an important bias leading to a misdiagnosis of autism. Indeed, ASD is often misdiagnosed in individuals with severe intellectual disability. It should be noted that the diagnosis of autism might be not valid or relevant for genetic disorders associated with severe intellectual disability due to first, the behavioral overlap between severe intellectual disability and autistic behavioral impairments (social communication deficit as well as repeated behaviors or interests), and second, the absence of validity and reliability of autism diagnostic instruments in the context of very low IQ or mental age of less than 24 months [255]. It is noteworthy that the most currently international instruments used for autism diagnosis, such as the ADI-R and the ADOS scales, were not normed in individuals with severe intellectual disability [255]. Cognitive functioning can be assessed, whenever possible with the child, by a psychologist or a neuropsychologist if available, using the age-appropriate Wechsler intelligence scales (Wechsler Preschool and Primary Scale of Intelligence: WPPSI-IV for children between 2 and 7 years old, Wechsler Intelligence Scale for Children: WISC-5 for children between 6 and 16 years old, Wechsler Adult Intelligence Scale: WAIS-IV for individuals above 16 years old) or the Kaufman Assessment Battery for Children (K-ABC) [256]. The Kaufman K-ABC is supposed to be more adapted for nonverbal children but cognitive assessment appears in fact easier to perform using the Wechsler intelligence scales with nonverbal subtests for nonverbal ASD children. Some instruments are of particular interest for intellectual disabled children with ASD.
such as the Raven’s Color Progressive Matrices (CPM) which is a short (20 min) nonverbal intelligence test validated for young children and individuals with intellectual disability [257].

The child psychiatric evaluation and psychological evaluation confirming autism diagnosis from different observational sources and assessing autism severity and intellectual disability are followed by a neuropediatrician’s evaluation and a geneticist’s evaluation (see Figure 1).
Figure 1. Hierarchical diagnostic strategy with a stepwise evaluation towards identification of genetic disorders associated with autism.
3.1.2. Developmental Milestones (Neuropediatric Evaluation)

A neuropediatric examination should be systematically conducted searching for neurological symptoms associated with ASD such as hypotonia, ataxia, abnormal movements or epilepsy. In case of clinical symptoms of epilepsy, the electroencephalogram (EEG) can be a useful tool to detect epileptic brain activity. In complement to this neuropediatric examination, it is necessary to rule out a sensory deficit, such as an auditory or visual deficit, based on ophthalmological and ears-nose-throat examination (an audiogram is recommended). In addition, the neuropediatric examination investigates extensively developmental milestones for the following periods (some developmental milestones are often explored also during the child psychiatric evaluation): (i) prenatal period: course of pregnancy, fetal movements, results of ultrasound exams, treatments (in particular, in-utero exposure to thalidomide or valproate, known as teratogenic medications and risk factors for ASD), and other possible prenatal risk factors for ASD (such as gestational diabetes, gestational bleeding or multiple birth [6]); (ii) perinatal period: birth presentation (abnormal presentation in general and breech presentation in particular, have been associated with the development of ASD [258], mode of delivery, clinical status at birth (APGAR, score, weight, body length, and head circumference), premature birth (the risk for autism increased with the severity of preterm birth [259]), conditions related to hypoxia at birth reported as risk factors for ASD (such as umbilical cord complications, meconium aspiration, neonatal anaemia, ABO or Rh incompatibility, hyperbilirubinemia, or birth injury and trauma; for a review, see Gardener et al. [260]), feeding pattern and difficulties, screening tests (hypothyroidism, phenylketonuria), physical examination (neonatal hypotonia); and (iii) postnatal period: psychomotor development, feeding pattern and possible gastrointestinal problems, sleep pattern, epilepsy, sensory dysfunction, language development, early behavioral signs of autism and other atypical behaviors. This clinical evaluation investigates developmental and learning disorders. The study of the height-weight-head circumference growth curve can show a break, decline with regression, or decrease with stagnation. For example, a decrease between 6 and 18 months of head circumference growth should orient the clinician towards the search for Rett syndrome in its first stage (stagnation stage) which occurs before the stage of fast decline of the communication skills (regression stage between 12 and 18 months of age). In addition, a developmental regression should orient the clinician towards the search for metabolic diseases. More generally, neuroimaging is recommended in individuals with ASD and microcephaly [249]. It is noteworthy that parental measures of height-weight-head circumference have also to be considered in order to determine whether the child’s height-weight-head circumference measures are really abnormal compared to the parents’ ones or whether a parent may be mildly affected, orienting towards a congenital or acquired abnormality.

3.1.3. Physical Examination (Genetic Evaluation)

A clinical genetics evaluation is systematically required and involves an extensive physical examination of the whole body. This physical examination should be conducted by a clinical geneticist trained in dysmorphology searching for dysmorphic features or malformations, and includes photos of the head (face and profile) with a good visibility of the ears, hands (palm and dorsal view) and feet. When clinical geneticists are not easily available, alternative options are to send, as a preliminary step, patients’ pictures (face and hands pictures) to a geneticist for a specialized opinion (our group is testing the feasibility and efficiency of such a procedure and is comparing the results obtained based on the analyses of pictures by a group of geneticists to the ones obtained based on the analyses of the same pictures using the genetic search and reference mobile application Face2Gene developed by FDNA: Facial Dysmorphology Novel Analysis). In addition, the skin should be examined with a Wood lamp, in particular when tuberous sclerosis is suspected [251]. Finally, clinical genetics evaluation can greatly benefit, in this strategy of identification of genetic disorders associated with ASD, from examining repeatedly over time the child to follow his/her developmental trajectory and examining at the same time the patient, his/her parents and siblings to compare the findings.
3.2. Second Step: Complementary Investigations (Laboratory Studies)

This secondary investigation includes cytogenetic, molecular analyses, biochemical analyses. Other exams such as neuroimaging and EEG are requested based on the results of the clinical genetic and neuropediatric examinations.

The following hierarchical diagnostic strategy, in line with recent American guidelines [249], can be proposed (see Figure 1).

3.2.1. Non-Syndromic Autism (Isolated ASD)

It should be remembered that non-syndromic autism includes ASD individuals with moderate intellectual disability to normal cognitive functioning (high functioning ASD) and no other associated signs or symptoms (except the possible presence of seizures). To our knowledge, the probability to detect a mutation (CNV or point mutation) is very low in high functioning non-syndromic ASD individuals, and, in this case, we do not recommend molecular analysis. However, in the case of family history of psychiatric disorders or developmental disabilities, it could be of interest to perform aCGH and to collect samples for a research program. In addition, in the case of consanguinity or selective food aversion, it could be useful to perform targeted metabolic testing. In addition, in the case of individuals with intellectual disability or males with no intellectual disability, the search for Fragile X mutation is recommended. If there is no hypothesis, a repeated clinical genetic evaluation over time is proposed given the possible later appearance of dysmorphic features along with the developmental trajectory.

3.2.2. Syndromic Autism (ASD Associated with Dysmorphic Features and/or Malformations and/or Symptomatic or Cryptogenic Epilepsy, and/or Severe Intellectual Disability)

If a specific chromosomal or point mutation is suspected: perform aCGH or specific gene sequencing.

If a metabolic disorder is suspected based on developmental regression (regression observed on the growth curves, including macrocephaly and in particular microcephaly, but also developmental psychomotor regression or neuroregression/neurodegeneration with neurological symptoms), seizures and especially epilepsy (recurrent and refractory seizures), consanguinity and specific dysmorphism or other symptoms described below: perform targeted metabolic testing including measurements of ammonemia and lactatemia, urinary organic acids chromatography, plasmatic amino-acids chromatography, creatine metabolism, iron, vitamin D, glutathione, oxidative stress, and cerebral magnetic resonance spectroscopy combined with standard neuroimaging. A metabolic disease could also be suspected based on certain clinical symptoms, such as digestion-related symptoms (cyclic vomiting, selective eating or gastrointestinal problems), dermatologic and hair changes (rashes, pigmented skin eruptions, hypertrichosis or alopecia), lethargy with hypotonia/extrapyramidal signs (dystonia, abnormal movements), or multiple organ dysfunction (in particular, heart, liver, kidney). In addition, the search for metabolic disorders can be indicated by abnormal biological measures such as anemia or lactic acidosis, and more generally acid/base or electrolyte disturbances. Searching for metabolic disorders is important given the potential availability of treatments such as enzyomotherapy for certain metabolic diseases, diet low in phenylalanine for phenylketonuria due to the enzyme phenylalanine hydroxylase deficiency, or supplementation with folinic acid for cerebral folate deficiency. Several metabolic disorders associated with ASD are listed in Table 1 using the superscript #.

If a mitochondrial disorder is suspected based on repeated regressions after three years old, neurological abnormalities (including hypotonia) and multiple organ dysfunction: perform targeted mitochondrial testing including measurement of lactatemia. Abnormal neurologic examination and/or elevated plasma lactate concentration have been indeed found in mitochondrial diseases [260]. A mitochondrial disorder could be also suspected in case of ASD associated with loss of speech after a
febrile illness or immunization with encephalopathy [261]. Finally, it is noteworthy that mitochondrial disease (rare in ASD) has to be differentiated from mitochondrial dysfunction (common in ASD) [262].

If there is no hypothesis of specific syndrome: perform aCGH and molecular diagnosis of Fragile-X syndrome. Without any identified pathogenic variant, we recommend targeted New Generation Sequencing (NGS) on known genes (for example, panels of genes related to intellectual disability or epilepsy based on the clinical examination) or Whole Exome Sequencing (WES) if available.

4. Conclusions

The finality of the hierarchal diagnostic strategy proposed in this article is to identify genetic disorders associated with ASD based on a stepwise evaluation characterized by low invasiveness and cost but high accessibility, feasibility and adaptability of current knowledge and technology to the individual and his/her family. These clinical and laboratory investigations can lead to identify genetic disorders associated with ASD in 35%–40% of individuals [225,262]. The identification of a specific genetic syndrome associated with ASD has practical clinical implications, in terms of diagnostic strategies including early detection and prevention of co-morbidity related to the known medical risks of the genetic disorder, follow up adapted to the genetic disorder with a more precise prognosis, and therapeutic strategies with access to needed services, help provided by specific family associations or specific individualized treatment in some cases. In many cases, identification of genetic disorders does not lead to therapeutic implications but there are a few cases where enzymotherapy, food depletion or supplementation in certain metabolic diseases as well as administration of melatonin associated with acebutolol in Smith–Magenis syndrome have improved considerably the quality of life of patients and their families. It should be noted that sleep problems are frequent in ASD (prevalence of insomnia: 50%–80% [263]) and decreased nocturnal and/or diurnal levels of melatonin (a sleep neurohormone) have been reported in many ASD studies; trial studies support therapeutic benefits of melatonin use in ASD (for a review, see Tordjman et al. [116,264]). Furthermore, the identification of genetic disorders associated with ASD allows unique personalized genetic counseling adapted to each family with regard to the transmission risk to the descendants and the possibility of a prenatal or preimplant diagnosis in the perspective of a future pregnancy. According to the 2013 American guidelines [249], the genetic counselor should note the type of array technology used (e.g., oligonucleotide vs. single-nucleotide polymorphism arrays) and access major databases relevant to this technology in order to provide the best possible and adapted information for the family. Many parents of children with ASD worry about the autism risk for a future pregnancy and knowing that their impaired child has a de novo mutation can be very helpful concerning the decision to have another child. It can be noted that the majority of the found mutations or rearrangements occurs de novo and are therefore not inherited from the parents or relatives [262]. In the same vein, siblings of children with ASD are very often preoccupied by the possible genetic transmission of autism to their future children. This preoccupation is legitimate considering, for instance, that the sisters of a boy with Fragile X Syndrome, even if they express very few or no symptoms, have a risk of 50% to carry the mutation or premutation and therefore a risk of 50% to have a child with Fragile X Syndrome (more severely impaired if it is a male). It is noteworthy that genetic counseling is also offered to families of ASD individuals without identified etiology, using in this case epidemiologic studies, and in particular sibling recurrence-risk updated data [249]. In any case, genetic counseling provides helpful family guidance, and parents of children with ASD are often relieved that biological factors involved in the development of ASD are considered and possibly found when some of them might feel guilty with regard to the role of family environment in ASD. Interestingly, based on our experience and the experience of geneticists or neuropediatricians working with psychoanalysts [265], knowing the underlying genetic cause of a relative’s or patient’s disorder, far from fixing the family or caregiver representations with regard to genetic determinism, rather creates and stimulates new dynamics within the family as well as the caregiver team centered on the ASD individual and probably related to a better known developmental trajectory with therapeutic perspectives and a parental relief. Finally, given all these implications, it is essential that all individuals
(children but also adolescents and adults) with ASD can benefit from a clinical genetic examination and neuropediatric examination searching for associated signs or symptoms helping to identify known genetic disorders.

Acknowledgments: Funds from the Laboratory Psychology of Perception (LPP) were receiving for covering the costs to publish in open access.

Author Contributions: Cyrille Robert and Sylvie Tordjman wrote the manuscript; Sylvie Odent, Laurent Pasquier, David Cohen, Mélanie Fradin, Roberto Canitano and Léna Damaj revised the first draft of the paper; Sylvie Tordjman, Sylvie Odent and Laurent Pasquier modified the article according to the reviewers’ comments.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5), 5th ed.; American Psychiatric Association: Washington, DC, USA, 2013.
2. Carrey, N.J. Itard’s 1828 Memoire on Mutism caused by a lesion of the intellectual functions: A historical analysis. J. Am. Acad. Child Adolesc. Psychiatry 1995, 34, 1655–1661. [CrossRef] [PubMed]
3. Kanner, L. Austistic disturbances of affective contact. Nervous Child 1943, 32, 217–253.
4. Bleuler, E. Dementia Praecox oder Gruppe der Schizophrenien; Handbuch der Psychiatrie; Deuticke: Leipzig, Germany, 1911.
5. Asperger, H. Die autistischen psychopathen im kindesalter. Arch. Psychiatry Nervenkrankheiten 1944, 117, 73–136. [CrossRef]
6. Tordjman, S.; Somogyi, E.; Coulon, N.; Kermarrec, S.; Cohen, D.; Bronsard, G.; Bonnot, O.; Weismann-Arcache, C.; Bottol, M.; Lauth, B.; et al. Gene-environment interactions in autism spectrum disorders: Role of epigenetic mechanisms. Front. Psychiatry 2014, 5, 1–17. [CrossRef] [PubMed]
7. Abrahams, B.S.; Geschwind, D.H. Advances in autism genetics: On the threshold of a new neurobiology. Nat. Rev. Genet. 2008, 9, 341–355. [CrossRef] [PubMed]
8. Bill, B.R.; Geschwind, D.H. Genetic advances in autism: Heterogeneity and convergence on shared pathways. Curr. Opin. Genet. Dev. 2009, 19, 271–278. [CrossRef] [PubMed]
9. Muhle, R.; Trentacoste, S.V.; Rapin, I. The genetics of autism. Pediatrics 2004, 113, 472–486. [CrossRef]
10. Ronald, A.; Hoekstra, R.A. Autism spectrum disorders and autistic traits: A decade of new twin studies. Am. J. Med. Genet. 2011, 156, 255–274. [CrossRef] [PubMed]
11. Sandin, S.; Lichtenstein, P.; Kuja-Halkola, R.; Larsson, H.; Hultman, C.M.; Reichenberg, A. The familial risk of autism. JAMA 2014, 311, 1770–1777. [CrossRef] [PubMed]
12. Rosti, R.O.; Sadek, A.A.; Vaux, K.K.; Gleeson, J.G. The genetic landscape of autism spectrum disorders. Dev. Med. Child Neurol. 2014, 56, 12–18. [CrossRef] [PubMed]
13. Sebat, J.; Lakshmi, B.; Malhotra, D.; Troge, J.; Lese-Martin, C.; Walsh, T. Strong association of de novo copy number mutations with autism. Science 2007, 316, 445–449. [CrossRef] [PubMed]
14. Hegmann, J.P.; Possidente, B. Estimating genetic correlations from inbred strains. Behav. Genet. 1981, 11, 103–114. [CrossRef] [PubMed]
15. Miles, J.H. Autism spectrum disorders, a genetics review. Genet. Med. 2011, 13, 278–294. [CrossRef] [PubMed]
16. Bourgeron, T. From the genetic architecture to synaptic plasticity in autism spectrum disorder. Nat. Rev. Neurosci. 2015, 16, 551–563. [CrossRef] [PubMed]
17. Miles, J.H.; Hillman, R.E. Value of a clinical morphology examination in autism. Am. J. Med. Genet. 2000, 91, 245–253. [CrossRef]
18. Jacquemont, M.L.; Sanlaville, D.; Redon, R.; Raoul, O.; Cormier-Daire, V.; Lyonnet, S.; Amiel, J.; Le Merrer, M.; Heron, D.; de Blois, M.C.; et al. Array-based comparative genomic hybridisation identifies high frequency of cryptic chromosomal rearrangements in patients with syndromic autism spectrum disorders. J. Med. Genet. 2006, 43, 843–849. [CrossRef] [PubMed]
19. Miles, J.H.; Takahashi, T.N.; Bagby, S.; Sahota, P.K.; Vaslow, D.F.; Wang, C.H.; Hillman, R.E.; Farmer, J.E. Essential versus complex autism: Definition of fundamental prognostic subtypes. Am. J. Med. Genet. 2005, 135, 171–180. [CrossRef] [PubMed]
20. Cohen, D.; Pichard, N.; Tordjman, S.; Baumann, C.; Burglen, L.; Excoffier, E.; Lazar, G.; Mazet, P.; Pinquier, C.; Verloes, A.; et al. Specific genetic disorders and autism: Clinical contribution towards their identification. *J. Autism Dev. Disord.* 2005, 35, 103–116. [CrossRef] [PubMed]

21. Amiet, C.; Gourfinkel-An, I.; Bouzamondo, A.; Tordjman, S.; Baulac, M.; Lechat, P.; Cohen, D.J. Epilepsy in autism is associated with intellectual disability and gender: Evidence from a meta-analysis. *Biol. Psychiatry* 2008, 64, 577–582. [CrossRef] [PubMed]

22. Amiet, C.; Gourfinkel-An, I.; Lauent, C.; Bodeneau, N.; Genin, B.; Leguern, E.; Tordjman, S.; Cohen, D.J. Does epilepsy in multiplex autism define a different subgroup of clinical characteristics and genetic risk? *Mol. Autism* 2013, 4, 47. [CrossRef] [PubMed]

23. Amiet, C.; Gourfinkel-An, I.; Lauent, C.; Carayol, J.; Genin, B.; Leguern, E.; Tordjman, S.; Cohen, D.J. Epilepsy in simplex autism pedigrees is much lower than the rate in multiplex autism pedigrees. *Biol. Psychiatry* 2013, 74, 3–4. [CrossRef] [PubMed]

24. Canitano, R. Epilepsy in autism spectrum disorders. *Eur. Child Adolesc. Psychiatry* 2007, 16, 61–66. [CrossRef] [PubMed]

25. Tordjman, S.; Cohen, D.; Anderson, G.M.; Canitano, R.; Botbol, M.; Coulon, N.; Roubertoux, P.L. Reframing autism as a behavioral syndrome and not a specific mental disorder: Implications of genetic and phenotypic heterogeneity. *Neurosci. Biobehav. Rev.* 2017. [CrossRef] [PubMed]

26. Cook, E.H., Jr.; Lindgren, V.; Leventhal, B.L.; Courchesne, R.; Lincoln, A.; Shulman, C.; Lord, C.; Courchesne, E. Autism or atypical autism in maternally but not paternally derived proximal 15q duplication. *Am. J. Hum. Genet.* 1997, 60, 928–934. [PubMed]

27. Bolton, P.F.; Dennis, N.R.; Browne, C.E.; Thomas, N.S.; Veltman, M.W.; Thompson, R.J.; Jacobs, P. The phenotypic manifestations of interstitial duplications of proximal 15q with special reference to the autistic spectrum disorders. *Am. J. Hum. Genet.* 2001, 105, 675–685. [CrossRef] [PubMed]

28. Cohen, D.; Martel, C.; Wilson, A.; Déchambre, N.; Amy, C.; Duverger, L.; Guile, J.M.; Pipiras, E.; Benzacken, B.; Cavé, H.; et al. Brief report: visual-spatial deficit in a 16-year-old girl with maternally derived duplication of proximal 15q. *J. Autism Dev. Disord.* 2007, 37, 1585–1591. [CrossRef] [PubMed]

29. Schroer, R.J.; Phelan, M.C.; Michaelis, R.C.; Crawford, E.C.; Skinner, S.A.; Cuccaro, M.; Simensen, R.J.; Bishop, J.; Skinner, C.; Fender, D.; et al. Autism and maternally derived aberrations of chromosome 15q. *Am. J. Hum. Genet.* 1998, 76, 327–336. [CrossRef]

30. Wandstrat, A.E.; Leana-Cox, J.; Jenkins, L.; Schwartz, S. Molecular cytogenetic evidence for a common break-point in the largest inverted duplications for chromosomes 15. *Am. J. Hum. Genet.* 1998, 62, 925–936. [PubMed]

31. Sutcliffe, J.S.; Nurmi, E.L. Genetics of childhood disorders: XLVII. Autism, Part 6: Duplication and inherited susceptibility of chromosome 15q11–q13 genes in autism. *J. Am. Acad. Child Adolesc. Psychiatry* 2003, 42, 253–256. [CrossRef] [PubMed]

32. Jacobsen, J.; King, B.H.; Leventhal, B.L.; Christian, S.L.; Ledbetter, D.H.; Cook, E.H., Jr. Molecular screening for proximal 15q abnormalities in a mentally retarded population. *J. Med. Genet.* 1998, 35, 534–538. [CrossRef] [PubMed]

33. Steffenburg, S.; Gillberg, C.L.; Seffenburg, U.; Kyllerman, M. Autism in Angelman syndrome: A population-based study. *Pediatr. Neurol.* 1996, 14, 131–136. [CrossRef]

34. Peters, S.U.; Beaudet, A.L.; Madduri, N.; Bacino, C.A. Autism in Angelman syndrome: Implications for autism research. *Clin. Genet.* 2004, 66, 530–536. [CrossRef] [PubMed]

35. Chamberlain, S.J.; Chen, P.F.; Ng, K.Y.; Bourgeois-Rocha, F.; Lemtiri-Chlieh, F.; Levine, E.S.; Lalande, M. Induced pluripotent stem cell models of the genomic imprinting disorders Angelman and Prader-Willi syndromes. *Proc. Natl. Acad. Sci. USA* 2010, 107, 17668–17673. [CrossRef] [PubMed]

36. Rangasamy, S.; D’Mello, S.R.; Narayanan, V. Epigenetics, autism spectrum, and neurodevelopmental disorders. *Neurotherapeutics* 2013, 10, 742–756. [CrossRef] [PubMed]

37. Grafodatskaya, D.; Chung, B.; Szatmari, P.; Weksberg, R. Autism spectrum disorders and epigenetics. *J. Am. Acad. Child Adolesc. Psychiatry* 2010, 49, 794–809. [CrossRef] [PubMed]

38. Dawson, A.J.; Cox, J.; Hovaness, K.; Spriggs, E. PWS/AS MS-MLPA confirms maternal origin of 15q11.2 microduplication. *Case Rep. Genet.* 2015, 2015, 474097. [CrossRef] [PubMed]
39. Huang, H.S.; Allen, J.A.; Mabb, A.M. Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons. *Nature* 2011, 481, 185–189. [CrossRef] [PubMed]

40. Mabb, A.M.; Judson, M.C.; Zylka, M.J.; Philpot, B.D. Angelman syndrome: Insights into genomic imprinting and neurodevelopmental phenotypes. *Trends Neurosci.* 2011, 34, 293–303. [CrossRef] [PubMed]

41. Erickson, C.A.; Wink, L.K.; Baindu, B.; Ray, B.; Schaefer, T.L.; Pedapati, E.V.; Lahiri, D.K. Analysis of peripheral amyloid precursor protein in Angelman syndrome. *Am. J. Med. Genet.* 2016, 170, 2334–2337. [CrossRef] [PubMed]

42. Li, W.; Yao, A.; Zhi, H.; Kaur, K.; Zhu, Y.; Jia, M.; Wang, Q.; Jin, S.; Zhao, G.; et al. Angelman syndrome protein Ube3a regulates synaptic growth and endocytosis by inhibiting BMP signaling in Drosophila. *PLoS Genet.* 2016, 12, e1006062. [CrossRef] [PubMed]

43. Meng, L.; Person, R.E.; Beaudet, A.L. Ube3a-ATS is an atypical RNA polymerase II transcript that represses the paternal expression of Ube3a. *Hum. Mol. Genet.* 2012, 21, 3001–3012. [CrossRef] [PubMed]

44. Kishino, T.; Lalande, M.; Wasgstaff, J. UBE3A/E6-AP mutations cause Angelman syndrome. *Nat. Genet.* 1997, 15, 70–73. [CrossRef] [PubMed]

45. Pett, E.; Hérault, J.; Martineau, J.; Perrot, A.; Barthélémy, C.; Hameury, L.; Sauvage, D.; Lelord, G.; Müh, J.P. Association study with two markers of a human homeogene in infantile autism. *J. Med. Genet.* 1995, 32, 269–274. [CrossRef] [PubMed]

46. Clayton-Smith, J. Clinical research on Angelman syndrome in the United Kingdom: Observations on 82 affected individuals. *Am. J. Med. Genet.* 1993, 46, 12–15. [CrossRef] [PubMed]

47. Summers, J.A.; Allison, D.B.; Lynch, P.S.; Sandler, L. Behaviour problems in Angelman syndrome. *J. Intellect. Disabil. Res.* 1995, 39, 97–106. [CrossRef] [PubMed]

48. Walz, N.C. Parent report of stereotyped behaviors, social interaction, and developmental disturbances in individuals with Angelman syndrome. *J. Autism Dev. Disord.* 2007, 37, 940–947. [CrossRef] [PubMed]

49. Dykens, E.M.; Cassidy, S.B. Correlates of maladaptive behavior in children and adults with Prader-Willi syndrome. *Am. J. Med. Genet.* 1995, 60, 546–549. [CrossRef] [PubMed]

50. Demb, H.B.; Papola, P. PDD and Prader-Willi syndrome. *J. Am. Acad. Child Adolesc. Psychiatry* 1995, 34, 539–540. [CrossRef] [PubMed]

51. Dykens, E.M.; Cassidy, S.B.; King, B.H. Maladaptive behavior differences in Prader-Willi syndrome due to paternal deletion versus maternal uniparental disomy. *Am. J. Ment. Retard.* 1993, 98, 10–26. [CrossRef] [PubMed]

52. Veltman, M.W.; Thompson, R.J.; Craig, E.E.; Dennis, N.R.; Roberts, S.E.; Moore, V.; Brown, J.A.; Bolton, P.F. A paternally inherited duplication in the Prader-Willi/Angelman syndrome critical region: A case and family study. *J. Autism Dev. Disord.* 2015, 35, 117–127. [CrossRef]

53. Descheemaeker, M.J.; Govers, V.; Vermeulen, P.; Fryns, J.P. Pervasive developmental disorders in Prader-Willi syndrome: The Leuven experience in 59 subjects and controls. *Am. J. Med. Genet.* 2006, 140, 1136–1142. [CrossRef] [PubMed]

54. Hogart, A.; Wu, D.; LaSalle, J.M.; Schanen, N.C. The comorbidity of autism with the genomic disorders of chromosome 15q11.2–q13. *Neurobiol. Dis.* 2010, 38, 181–191. [CrossRef] [PubMed]

55. Veltman, M.W.; Thompson, R.J.; Craig, E.E.; Dennis, N.R.; Roberts, S.E.; Moore, V.; Brown, J.A.; Bolton, P.F. A paternally inherited duplication in the Prader-Willi/Angelman syndrome critical region: A case and family study. *J. Autism Dev. Disord.* 2015, 35, 117–127. [CrossRef]

56. Buiting, K. Prader-Willi and Angelman syndrome. *Am. J. Med. Genet.* 2010, 154, 365–376. [CrossRef] [PubMed]

57. Cassidy, S.B.; Schwartz, S.; Miller, H.; Driscoll, D.J. Prader-Willi syndrome. *Genet. Med.* 2012, 14, 10–26. [CrossRef] [PubMed]

58. Bennett, J.A.; Germani, T.; Haqq, A.M.; Zwaigenbaum, L. Autism spectrum disorder in Prader-Willi syndrome: A systematic review. *Am. J. Med. Genet.* 2015, 167, 2936–2944. [CrossRef] [PubMed]

59. Veltman, M.W.; Thompson, R.J.; Craig, E.E.; Dennis, N.R.; Roberts, S.E.; Moore, V.; Brown, J.A.; Bolton, P.F. A paternally inherited duplication in the Prader-Willi/Angelman syndrome critical region: A case and family study. *J. Autism Dev. Disord.* 2015, 35, 117–127. [CrossRef] [PubMed]

60. Bolton, P.F.; Roobol, M.; Allsopp, L.; Pickles, A. Association between idiopathic infantile macrocephaly and autism spectrum disorders. *Lancet* 2001, 358, 726–727. [CrossRef] [PubMed]

61. Roberts, S.E.; Dennis, N.R.; Browne, C.E.; Willatt, L.; Woods, G.; Cross, I.; Jacobs, P.A.; Thomas, S. Characterisation of interstitial duplications and triplications of chromosome 15q11–q13. *Hum. Genet.* 2002, 110, 227–234. [CrossRef] [PubMed]
62. Goizet, C.; Excoffier, E.; Taine, L.; Taupiac, E.; El Moneim, A.A.; Arveiler, B.; Bouvard, M.; Lacombe, D. Case with autistic syndrome and chromosome 22q13.3 deletion detected by FISH. *Am. J. Hum. Genet.* 2000, 96, 839–844. [CrossRef] [PubMed]

63. Manning, M.A.; Cassidy, S.B.; Clericuzio, C.; Cherry, A.M.; Schwartz, S.; Hudgins, L.; Enns, G.M.; Hoyme, H.E. Terminal 22q deletion syndrome: A newly recognized cause of speech and language disability in the autism spectrum. *Pediatrics* 2004, 114, 451–457. [CrossRef] [PubMed]

64. Prasad, C.; Prasad, A.N.; Chodirker, B.N.; Lee, C.; Dawson, A.K.; Jocelyn, L.J.; Chudley, A.E. Genetic evaluation of pervasive developmental disorders: The terminal 22q13 deletion syndrome may represent a recognizable phenotype. *Clin. Genet.* 2000, 57, 103–109. [CrossRef] [PubMed]

65. Phelan, M.C.; Rogers, R.C.; Saul, R.A.; Stapleton, G.A.; Sweet, K.; McDermid, H.; Shaw, S.R.; Claytor, J.; Willis, J.; Kelly, D.P. 22q13 Deletion Syndrome. *Am. J. Hum. Genet.* 2001, 101, 91–99. [CrossRef] [PubMed]

66. Soorya, L.; Kolevzon, A.; Zweifach, J.; Lim, T.; Dobry, Y.; Schwartz, L.; Frank, Y.; Wang, A.T.; Cai, G.; Parkhomenko, E.; et al. Prospective investigation of autism and genotype-phenotype correlations in 22q13 deletion syndrome and SHANK3 deficiency. *Mol. Autism* 2013, 4, 18. [CrossRef] [PubMed]

67. Shcheglovitov, A.; Shcheglovitova, O.; Yazawa, M.; Portmann, T.; Shu, R.; Sebastiano, V.; Krawisz, A.; Froehlich, W.; Bernstein, J.A.; Hallmayer, J.F.; et al. SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients. *Nature* 2013, 503, 267–271. [CrossRef] [PubMed]

68. Phelan, K.; McDermid, H.E. The 22q13.3 deletion syndrome (Phelan-McDermid syndrome). *Mol. Syndromol.* 2012, 2, 186–201. [CrossRef] [PubMed]

69. Peca, J.; Feliciano, C.; Ting, J.T.; Wang, W.; Wells, M.F.; Venkatraman, T.N.; Lascola, C.D.; Fu, Z.; Feng, G. SHANK3 mutant mice display autistic-like behaviours and striatal dysfunction. *Nature* 2011, 472, 437–442. [CrossRef] [PubMed]

70. Jafri, F.; Fink, J.; Higgins, R.R.; Tervo, R. 22q13.32 deletion and duplication and inversion in the same family: A rare occurrence. *ISRN Pediatr.* 2011, 2011, 829825. [CrossRef] [PubMed]

71. Zwanenburg, R.J.; Ruiter, S.A.J.; van Den Heuvel, E.R.; Flapper, B.C.T.; van Ravenswaaij-Arts, C.M.A. Developmental phenotype in Phelan-McDermid (22q13.3 deletion) syndrome: A systematic and prospective study in 34 children. *J. Neurogenet. Disord.* 2016, 8, 16. [CrossRef] [PubMed]

72. Marshall, C.R.; Noor, A.; Vincent, J.B.; Lionel, A.C.; Feuk, L.; Skaug, J.; Shago, M.; Enns, Y.; et al. Structural variation of chromosomes in autism spectrum disorder. *Am. J. Hum. Genet.* 2008, 82, 477–488. [CrossRef] [PubMed]

73. Hans, E.; Nasir, R.H.; Fong, A.; Lian, A.; Hundley, R.; Shen, Y.; Wu, B.L.; Holm, I.A.; Miller, D.T. 16p11.2 Study group clinicians cognitive and behavioral characterization of 16p11.2 deletion syndrome. *J. Dev. Behav. Pediatr.* 2010, 31, 649–657. [CrossRef] [PubMed]

74. Weiss, L.A.; Shen, Y.; Korn, J.M.; Arking, D.E.; Miller, D.T.; Fossdal, R.; Saemundsen, E.; Stefansson, H.; Ferreira, M.A.; Green, T.; et al. Consortium association between microdeletion and microduplication at 16p11.2 and autism. *New Engl. J. Med.* 2008, 358, 667–675. [CrossRef] [PubMed]

75. Kumar, R.A.; KaraMohamed, S.; Sudi, J.; Conrad, D.F.; Brune, C.; Badner, J.A.; Gilliam, T.C.; Nowak, N.J.; Cook, E., Jr.; Dobyns, W.B.; et al. Recurrent 16p11.2 microdeletions in autism. *Hum. Mol. Genet.* 2008, 17, 628–638. [CrossRef] [PubMed]

76. Fombonne, E.; Du Mazaubrun, C.; Cans, C.; Grandjean, H. Autism and associated medical disorders in a French epidemiological survey. *Clin. Genet.* 2004, 65, 561–567. [CrossRef] [PubMed]

77. Steinman, K.J.; Spence, S.J.; Ramocki, M.B.; Proud, M.B.; Kessler, S.K.; Marco, E.J.; Green Snyder, L.; D’Angelo, D.; Chen, Q.; Chung, W.K.; et al. 16p11.2 Deletion and duplication: Characterizing neurologic phenotypes in a large clinically ascertained cohort. *Am. J. Med. Genet.* 2016, 169A, 1–13. [CrossRef] [PubMed]

78. Green Snyder, L.; D’Angelo, D.; Chen, Q.; Bernier, R.; Goin-Kochel, R.P.; Wallace, A.S.; Gerdts, J.; Kane, S.; Berry, L.; Blaskey, L.; et al. Autism spectrum disorder, developmental and psychiatric features in 16p11.2 duplication. *J. Autism Dev. Disord.* 2016, 46, 2734–2748. [CrossRef] [PubMed]

79. Fisch, G.S.; Grossfeld, P.; Falk, R.; Battaglia, A.; Youngblom, J.; Simensen, R. Cognitive-behavioral features of Wolf-Hirschhorn syndrome and other subtelomeric microdeletions. *Am. J. Med. Genet.* 2010, 154, 417–426. [CrossRef] [PubMed]

80. Fisch, G.S.; Davis, R.; Youngblom, J.; Gregg, J. Genotype-phenotype association studies of chromosome 8p inverted duplication deletion syndrome. *Behav. Genet.* 2011, 41, 373–380. [CrossRef] [PubMed]
81. Bregmen, J.D.; Volkmar, F.R. Autism spectrum disorders in genetic syndromes: Implications for diagnosis, intervention and understanding the wider autism spectrum disorder population. *J. Intellect. Disabil. Res.* 1988, 53, 852–873.

82. Mariner, R.; Jackson, A.W.; Levitas, A.; Hagerman, R.J.; Braden, M.; Mcbogg, P.M.; Smith, A.C.; Berry, R. Autism, mental retardation, and chromosomal abnormalities. *J. Autism Dev. Disord.* 1986, 16, 425–440. [CrossRef] [PubMed]

83. Ghaziuddin, M. Autism in down syndrome: Family history correlates. *J. Intellect. Disabil. Res.* 1997, 41, 87–91. [CrossRef] [PubMed]

84. Moss, J.; Howlin, P. Autism spectrum disorders in genetic syndromes: Implications for diagnosis, intervention and understanding the wider autism spectrum disorder population. *J. Intellect. Disabil. Res.* 2009, 53, 852–873. [CrossRef] [PubMed]

85. Jiang, J.; Jing, Y.; Cost, G.J.; Chiang, J.C.; Kolpa, H.J.; Cotton, A.M.; Carone, D.M.; Carone, B.R.; Shivak, D.A.; Guschin, D.Y.; et al. Translating dosage compensation to trisomy 21. *Nature* 2013, 500, 296–300. [CrossRef] [PubMed]

86. Smith, A.C.; McGavran, L.; Robinson, J.; Waldstein, G.; Macfarlane, J.; Zonona, J.; Reiss, J.; Lahr, M.; Allen, L.; Magenis, E. Interstitial deletion of (17) (P11.2p11.2) in nine patients. *Am. J. Hum. Genet.* 1986, 24, 393–414. [CrossRef] [PubMed]

87. Vostanis, P.; Harrington, R.; Prendergast, M.; Farndon, P. Case reports of autism with interstitial deletion of chromosome 17 (p11.2 p11.2) and monosomy of chromosome 5 (5pter > 5p15.3). *Psychiatr. Genet.* 1994, 4, 109–111. [CrossRef] [PubMed]

88. Laje, G.; Morse, R.; Richter, W.; Ball, J.; Pao, M.; Smith, A.C.M. Autism spectrum features in smith-magenis syndrome. *Am. J. Med. Genet.* 2010, 154, 456–462. [CrossRef] [PubMed]

89. Potocki, L.; Bi, W.; Treadwell-Deering, D.; Carvalho, C.M.; Eifert, A.; Friedman, E.M.; Glaze, D.; Krull, K.; Lee, J.A.; Lewis, R.A.; et al. Characterization of Potocki-Lupski syndrome (dup(17) (p11.2p11.2)) and delineation of a dosage-sensitive critical interval that can convey an autism phenotype. *Am. J. Med. Genet.* 2007, 80, 633–649. [CrossRef] [PubMed]

90. Ghaziuddin, M.; Burmeister, M. Deletion of chromosome 2q37 and autism: A distinct subtype? *J. Autism Dev. Disord.* 1999, 29, 259–263. [CrossRef] [PubMed]

91. Devillard, F.; Guinchat, V.; Moreno-De-Luca, D.; Tabet, A.C.; Gruchy, N.; Guillem, P.; Nguyen Morel, M.A.; Leporrier, N.; Leboyer, M.; Jouk, P.; et al. Paracentric inversion of chromosome 2 associated with cryptic duplication of 2q14 and deletion of 2q37 in a patient with autism. *Am. J. Med. Genet.* 2010, 152, 2346–2354. [CrossRef] [PubMed]

92. Galasso, C.; Lo-Castro, A.; Lalli, C.; Nardone, A.M.; Gullotta, F.; Curatolo, P. Deletion 2q37: An identifiable clinical syndrome with mental retardation and autism. *J. Child Neurol.* 2008, 23, 802–806. [CrossRef] [PubMed]

93. Falk, R.E.; Casas, K.A. Chromosome 2q37 deletion: Clinical and molecular aspects. *Am. J. Med. Genet.* 2007, 145, 357–371. [CrossRef] [PubMed]

94. Fisch, G.S.; Falk, R.E.; Carey, J.C.; Imitola, J.; Sederberg, M.; Caravalho, K.S.; South, S. Deletion 2q37 syndrome: Cognitive-Behavioral trajectories and autistic features related to breakpoint and deletion size. *Am. J. Med. Genet.* 2016, 170, 2282–2291. [CrossRef] [PubMed]

95. Lo-Castro, A.; Galasso, C.; Cerminara, C.; El-Malhany, N.; Benedetti, S.; Nardone, A.M.; Curatolo, P. Association of syndromic mental retardation and autism with 22q11.2 duplication. *Neuropediatrics* 2009, 40, 137–140. [CrossRef] [PubMed]

96. Lo-Castro, A.; Benvenuto, A.; Galasso, C.; Porfirio, C.; Curatolo, P. Autism spectrum disorders associated with chromosomal abnormalities. *Res. Autism Spectr. Disord.* 2010, 4, 319–327. [CrossRef] [PubMed]

97. Portnoi, M.F. Microduplication 22q11.2: A new chromosomal syndrome. *Eur. J. Med. Genet.* 2009, 52, 88–93. [CrossRef] [PubMed]

98. Baker, K.D.; Skuse, D.H. Adolescents and young adults with 22q11 deletion syndrome: Psychopathology in an at-risk group. *Br. J. Psychiatry* 2005, 186, 115–120. [CrossRef] [PubMed]

99. Wenger, T.L.; Miller, J.S.; DePolo, L.M.; de Marchena, A.B.; Clements, C.C.; Emanuel, B.S.; Zackai, E.H.; McDonald-McGinn, D.M.; Schultz, R.T. 22q11.2 duplication syndrome: Elevated rate of autism spectrum disorder and need for medical screening. *Mol. Autism* 2016, 7, 27. [CrossRef] [PubMed]
100. Hidding, E.; Swaab, H.; de Sonneville, L.M.J.; van Engeland, H.; Vorstman, J.A.S. The role of COMT and plasma proline in the variable penetrance of autistic spectrum symptoms in 22q11.2 deletion syndrome. *Clin. Genet.* 2016, 90, 420–427. [CrossRef] [PubMed]

101. Mefford, H.C.; Sharp, A.J.; Baker, C.; Itsara, A.; Jiang, Z.; Buysse, K.; Huang, S.; Maloney, V.K.; Crolla, J.A.; Baralle, D.; et al. Recurrent rearrangements of chromosome 1q21.1 and variable pediatric phenotypes. *N. Engl. J. Med.* 2008, 359, 1685–1699. [CrossRef] [PubMed]

102. Brunetti-Pierri, N.; Berg, J.S.; Scaglia, F.; Belmont, J.; Bacino, C.A.; Sahoo, T.; Lalani, S.R.; Graham, B.; Lee, B.; Shinawi, M.; et al. Recurrent reciprocal 1q21.1 deletions and duplications associated with microcephaly or macrocephaly and developmental and behavioral abnormalities. *Nat. Genet.* 2008, 40, 1466–1471. [CrossRef] [PubMed]

103. Bernier, R.; Steinman, K.J.; Reilly, B.; Wallace, A.S.; Sherr, E.H.; Pojman, N.; Mefford, H.C.; Gerdts, J.; Earl, R.; Hanson, E.; et al. Clinical phenotype of the recurrent 1q21.1 copy-number variant. *Gen. Med.* 2016, 18, 341–349. [CrossRef] [PubMed]

104. Torres, F.; Barbosa, M.; Maciel, P. Recurrent copy number variations as risk factors for neurodevelopmental disorders: Critical overview and analysis of clinical implications. *J. Med. Genet.* 2016, 53, 73–90. [CrossRef] [PubMed]

105. berg, J.S.; Brunetti-Pierri, N.; Peters, S.U.; Kang, S.H.; Fong, C.T.; Salamone, J.; Freedenberg, D.; Hannig, V.L.; Prock, L.A.; Miller, D.T.; et al. Speech delay and autism spectrum behaviors are frequently associated with duplication of the 7q11.23 Williams-Beuren syndrome region. *Genet. Med.* 2007, 9, 427–441. [CrossRef] [PubMed]

106. Depienne, C.; Heron, D.; Betancur, C.; Benyahia, B.; Trouillard, O.; Bouteiller, D.; Verloes, A.; LeGuerin, E.; Leboyer, M.; Brice, A. Autism, language delay and mental retardation in a patient with 7q11 duplication. *J. Med. Genet.* 2007, 44, 452–458. [CrossRef] [PubMed]

107. Edelmann, L.; Prosnitz, A.; Pardo, S.; Bhatt, J.; Cohen, N.; Lauriat, T.; Ouchanov, L.; González, P.J.; Manghi, E.R.; Bondy, P.; et al. An atypical deletion of the Williams-Beuren syndrome interval implicates genes associated with defective visuospatial processing and autism. *J. Med. Genet.* 2007, 44, 136–143. [CrossRef] [PubMed]

108. Gagliardi, C.; Bonaglia, M.C.; Selicorni, A.; Borgatti, R.; Giorda, R. Unusual cognitive and behavioural profile in a Williams syndrome patient with atypical 7q11.23 deletion. *J. Med. Genet.* 2003, 40, 526–530. [CrossRef] [PubMed]

109. Lincoln, A.J.; Searcy, Y.M.; Jones, W.; Lord, C. Social interaction behaviors discriminate young children with autism and Williams syndrome. *J. Am. Acad. Child Adolesc. Psychiatry* 2007, 46, 323–331. [CrossRef] [PubMed]

110. Sanders, S.J.; Ercan-Sencicek, A.G.; Hus, V.; Luo, R.; Murtha, M.T.; Moreno-de-Luca, D.; Chu, S.H.; Moreau, M.P.; Gupta, A.R.; Thomson, S.A.; et al. Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams-beuren syndrome region, are strongly associated with autism. *Neuron* 2011, 70, 863–885. [CrossRef] [PubMed]

111. Somerville, M.J.; Mervis, C.B.; Young, E.J.; Seo, E.J.; del Campo, M.; Bamforth, S.; Peregrine, E.; Loo, W.; Lilley, M.; Pérez-Jurado, L.A.; et al. Severe expressive-language delay related to duplication of the Williams-Beuren locus. *N. Engl. J. Med.* 2005, 353, 1694–1701. [CrossRef] [PubMed]

112. Van der Aa, N.; Rooms, L.; Vandeweyer, G.; van den Ende, J.; Reyniers, E.; Fichera, M.; Romano, C.; Delle Chiaie, B.; Mortier, G.; Menten, B.; et al. Fourteen new cases contribute to the characterization of the 7q11.23 microduplication syndrome. *Eur. J. Hum. Genet.* 2009, 52, 94–100. [CrossRef] [PubMed]

113. Makeyev, A.V.; Enkhamandakh, B.; Hong, S.H.; Joshi, P.; Shin, D.G.; Bayarsaikhan, D. Diversity and complexity in chromatin recognition by TFII-I transcription factors in pluripotent embryonic stem cells and embryonic tissues. *PLoS ONE* 2012, 7, e44443. [CrossRef] [PubMed]

114. Tordjman, S.; Anderson, G.M.; Botbol, M.; Toutain, A.; Sarda, P.; Carlier, M.; Saugier-Veber, P.; Baumann, C.; Cohen, D.; Lagneaux, C.; et al. Autistic disorder in patients with Williams-Beuren syndrome: A reconsideration of the Williams-Beuren syndrome phenotype. *PLoS ONE* 2012, 7, e30778. [CrossRef] [PubMed]

115. Tordjman, S.; Anderson, G.M.; Cohen, D.; Kermarrec, S.; Carlier, M.; Touitou, Y.; Saugier-Veber, P.; Lagneaux, C.; Chevreuil, C.; Verloes, A. Presence of autism, hyperserotonemia, and severe expressive language impairment in Williams-Beuren syndrome. *Mol. Autism* 2013, 4, 29. [CrossRef] [PubMed]
116. Tordjman, S.; Najjar, I.; Bellissant, E.; Anderson, G.M.; Barburoth, M.; Cohen, D.; Jaafari, N.; Schischmanoff, O.; Fagard, R.; Lagdas, I.; et al. Advances in the research of melatonin in autism spectrum disorders: Literature review and new perspectives. *Int. J. Mol. Sci.* 2013, 14, 20508–20542. [CrossRef] [PubMed]

117. Richards, C.; Jones, C.; Groves, L.; Moss, J.; Oliver, C. Prevalence of autism spectrum disorder phenology in genetic disorders: A systematic review and meta-analysis. *Lancet Psychiatry* 2015, 2, 909–916. [CrossRef]

118. Skuse, D.H.; James, R.S.; Bishop, D.V.; Coppin, B.; Dalton, P.; Aamodt-Leeper, G.; Bacarese-Hamilton, M.; Creswell, C.; McGurk, R.; Jacobs, P.A. Evidence from Turner’s syndrome of an imprinted X-linked locus affecting cognitive function. *Nature* 1997, 387, 705–708. [CrossRef] [PubMed]

119. Sybert, V.P.; McCauley, E. Turner’ syndrome. *N. Engl. J. Med.* 2004, 351, 1227–1238. [CrossRef] [PubMed]

120. Kent, L.; Bowdin, S.; Kirby, G.A.; Cooper, W.N.; Maher, E.R. Beckwith Wiedemann syndrome: A behavioral phenotype-genotype study. *Am. Med. Genet.* 2008, 147, 1295–1297. [CrossRef] [PubMed]

121. DeBaun, M.R.; Niemitz, E.L.; Feinberg, A.P. Association of in vitro fertilization with Beckwith-Wiedemann syndrome and epigenetic alterations of LIT1 and H19. *Am. J. Hum. Genet.* 2003, 72, 156–160. [CrossRef] [PubMed]

122. Smith, A.C.; Choufani, S.; Ferreira, J.C.; Weksberg, R. Growth regulation, imprinted genes, and chromosome 11p15.5. *Pediatr. Res.* 2007, 61, 43–47. [CrossRef] [PubMed]

123. Weksberg, R.; Shuman, C.; Beckwith, J.B. Beckwith-Wiedemann syndrome. *Eur. J. Hum. Genet.* 2010, 18, 8–14. [CrossRef] [PubMed]

124. Wolpert, C.M.; Menold, M.M.; Bass, M.P.; Qumsiyeh, M.B.; Donnelly, S.L.; Ravan, S.A.; Vance, J.M.; Gilbert, J.R.; Abramson, R.K.; Wright, H.H.; et al. Three probands with autistic disorder and isodicentric chromosome 15. *Am. J. Med. Genet.* 2000, 96, 365–372. [CrossRef]

125. Wolpert, C.; Pericak-Vance, M.A.; Abramson, R.K.; Wright, H.H.; Cuccaro, M.L. Autistic symptoms among children and young adults with isodicentric chromosome 15. *Am. J. Med. Genet.* 2000, 96, 128–129. [CrossRef]

126. Parisi, L.; di Filippo, T.; Roccella, M. Hypomelanosis of ito: Neurological and psychiatric pictures in developmental age. *Minerva Pediatr.* 2012, 64, 65–70. [PubMed]

127. Åkefeldt, A.; Gillberg, C. Hypomelanosis of ito in three cases with autism and autistic-like conditions. *Dev. Med. Child Neurol.* 1991, 33, 737–743. [CrossRef] [PubMed]

128. Johansson, M.; Gillberg, C.; Råstam, M. Autism spectrum conditions in individuals with Möbius sequence, CHARGE syndrome and oculo-auriculo-vertebral spectrum: Diagnostic aspects. *Res. Dev. Disabil.* 2010, 31, 9–24. [CrossRef] [PubMed]

129. Johansson, M.; Råstam, M.; Billstedt, E.; Danielsson, S.; Strömland, K.; Miller, M.; Gillberg, C. Autism spectrum disorders and underlying brain pathology in CHARGE association. *Dev. Med. Child Neurol.* 2006, 48, 40–50. [CrossRef] [PubMed]

130. Smith, I.M.; Nichols, S.L.; Issekutz, K.; Blake, K. Canadian paediatric surveillance program behavioral profiles and symptoms of autism in CHARGE syndrome: Preliminary Canadian epidemiological data. *Am. J. Med. Genet.* 2005, 133, 248–256. [CrossRef] [PubMed]

131. Hartshorne, T.S.; Grialou, T.L.; Parker, K.R. Autistic-like behavior in CHARGE syndrome. *Am. J. Med. Genet.* 2005, 133, 257–261. [CrossRef] [PubMed]

132. Patten, S.A.; Jacobs-McDaniels, N.L.; Zaouter, C.; Drapeau, P.; Albertson, R.C.; Moldovan, F. Role of Chd7 in zebrafish: A model for CHARGE syndrome. *PloS ONE* 2012, 7, e31650. [CrossRef] [PubMed]

133. Blake, K.D.; Prasad, C. CHARGE syndrome. *Orphanet J. Rare Dis.* 2006, 1, 34. [CrossRef] [PubMed]

134. Bolton, P.F.; Park, R.J.; Higgins, J.N.; Griffiths, P.D.; Pickles, A. Neuro-epileptic determinants of autism spectrum disorders in tuberous sclerosis complex. *Brain* 2002, 125, 1247–1255. [CrossRef] [PubMed]

135. Curatolo, P.; Bombardieri, R.; Jozwiak, S. Tuberous sclerosis. *Lancet* 2008, 372, 657–668. [PubMed]

136. Jeste, S.S.; Varcin, K.J.; Hellemann, G.S.; Gulrsud, A.C.; Bhatt, R.; Kasari, C.; Wu, J.Y.; Sahin, M.; Nelson, C.A. Symptom profiles of autism spectrum disorder in tuberous sclerosis complex. *Neurology* 2016. [CrossRef] [PubMed]

137. McBride, K.L.; Varga, E.A.; Pastore, M.T.; Prior, T.W.; Manickam, K.; Atkin, J.F.; Herman, G.E. Confirmation study of PTEN mutations among individuals with autism or developmental delays/mental retardation and macrocephaly. *Autism Res.* 2010, 3, 137–141. [CrossRef] [PubMed]

138. Lintas, C.; Persico, A.M. Autistic phenotypes and genetic testing: State-of-the-art for the clinical geneticist. *J. Med. Genet.* 2009, 46, 1–8. [CrossRef] [PubMed]
139. Buxbaum, J.D.; Cai, G.; Chaste, P.; Nygren, G.; Goldsmith, J.; Reichert, J.; Anckarsäter, H.; Rastam, M.; Smith, C.J.; Silverman, J.M.; et al. Mutation screening of the PTEN gene in patients with autism spectrum disorders and macrocephaly. Am. J. Med. Genet. 2007, 144, 484–491. [CrossRef] [PubMed]
140. Herman, G.E.; Butter, E.; Enrile, B.; Pastore, M.; Prior, T.W.; Sommer, A. Increasing knowledge of PTEN germline mutations: Two additional patients with autism and macrocephaly. Am. J. Med. Genet. 2007, 143, 589–593. [CrossRef] [PubMed]
141. Goffin, A.; Hoefsloot, L.H.; Bosgoed, E.; Swillen, A.; Fryns, J.P. PTEN mutation in a family with Cowden syndrome and autism. Am. J. Med. Genet. 2001, 105, 521–524. [CrossRef] [PubMed]
142. Spinelli, L.; Black, F.M.; Berg, J.N.; Eickholt, B.J.; Leslie, N.R. Functionally distinct groups of inherited PTEN mutations in autism and tumour syndromes. J. Med. Genet. 2015, 52, 128–134. [CrossRef] [PubMed]
143. Amir, R.E.; Van Den Veyver, I.B.; Wan, M.; Tran, C.Q.; Francke, U.; Zoghbi, H.Y. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 1999, 23, 185–188. [PubMed]
144. Olsonn, B.; Rett, A. A review of the Rett syndrome with a theory of autism. Brain Dev. 1990, 12, 11–15. [CrossRef]
145. Ramaekers, V.T.; Blau, N. Cerebral folate deficiency. J. Ment. Defic. Res. 1983, 27, 185–203. [CrossRef] [PubMed]
146. Neul, J.L. The relationship of Rett syndrome and MECP2 disorders to autism. Dialogues Clin. Neurosci. 2012, 14, 253–262. [PubMed]
147. Gadalla, K.; Bailey, M.E.; Cobb, S.R. McGP2 and Rett syndrome: Reversibility and potential avenues for therapy. Biochem. J. 2011, 439, 1–14. [CrossRef] [PubMed]
148. Neul, J.L.; Kaufmann, W.E.; Glaze, D.G.; Christodoulou, J.; Angus, J.; Clarke, A.J.; Bahl-Buisson, N.; Leonard, H.; Bailey, M.E.S.; Schanen, C.; et al. Rett syndrome: Revised diagnostic criteria and nomenclature. Ann. Neurol. 2010, 68, 944–950. [CrossRef] [PubMed]
149. Ramocki, M.B.; Peters, S.U.; Tavhey, Y.J.; Zhang, F.; Carvalho, C.M.; Schaf, C.P.; Richman, R.; Fang, P.; Glaze, D.G.; Lupski, J.R.; et al. Autism and other neuropsychiatric symptoms are prevalent in individuals with McGP2 duplication syndrome. Ann. Neurol. 2009, 66, 771–782. [CrossRef] [PubMed]
150. Nidiffer, F.D.; Kelly, T.E. Developmental and degenerative patterns associated with cognitive, behavioural and motor difficulties in the Sanfilippo syndrome: An epidemiological study. J. Ment. Defic. Res. 1983, 27, 185–203. [CrossRef] [PubMed]
151. Wraith, J.E. The mucopolysaccharidoses: A clinical review and guide to management. Arch. Dis. Child. 1995, 72, 263–267. [CrossRef] [PubMed]
152. Ritvo, E.R.; Mason-Brothers, A.; Freeman, B.J.; Pingree, C.; Jenson, W.R.; McMahon, W.M.; Petersen, P.B.; Jorde, L.B.; Mo, A.; Ritvo, A. The UCLA-university of Utah epidemiologic survey of autism: The etiologic role of rare diseases. Am. J. Psychiatry 1990, 147, 1614–1621. [PubMed]
153. Shapiro, E.; King, K.; Ahmed, A.; Rudser, K.; Rumsey, R.; Yund, B.; Delaney, K.; Nestrasil, I.; Whitley, C.; Potegal, M. The neurobehavioral phenotype in mucopolysaccharidosis type IIIA: An exploratory study. Mol. Genet. Metab. Rep. 2016, 6, 41–47. [CrossRef] [PubMed]
154. Ramaekers, V.T.; Blau, N. Cerebral folate deficiency. Dev. Med. Child Neurol. 2004, 46, 843–851. [CrossRef] [PubMed]
155. Moretti, P.; Scaglia, F. Cerebral folate deficiency with developmental delay, autism, and response to folinic acid. Neurology 2005, 64, 1088–1090. [CrossRef] [PubMed]
156. Gordon, N. Cerebral folate deficiency. Dev. Med. Child Neurol. 2009, 51, 180–182. [CrossRef] [PubMed]
157. Raidah, S.A.; Mohammed, W.C. Diagnosis and management of cerebral folate deficiency. Neurosciences 2014, 19, 312–316.
158. Ryan, A.K.; Bartlett, K.; Clayton, P.; Eaton, S.; Mills, L.; Donnai, D.; Winter, R.M.; Burn, J. Smith-Lemli-Opitz syndrome: A variable clinical and biochemical phenotype. J. Med. Genet. 1998, 35, 558–565. [CrossRef] [PubMed]
159. Kelley, R.I.; Hennekam, R.C.M. The Smith-Lemli-Opitz syndrome. J. Med. Genet. 2000, 37, 321–335. [CrossRef] [PubMed]
160. Tierney, E.; Nwokoro, N.A.; Porter, F.D.; Freund, L.S.; Ghuman, J.K.; Kelley, R.I. Behavior phenotype in the RSH/Smith-Lemli-Opitz syndrome. Am. J. Med. Genet. 2001, 98, 191–200. [CrossRef]
161. Tierny, E.; Nwokoro, N.A.; Kelley, R.I. Behavior phenotype of RSH/Smith-Lemli-Opitz syndrome. *Ment. Retard. Dev. Disabil. Res. Rev. 2001, 98, 191–200.

162. Tint, G.S.; Irons, M.; Elias, E.R.; Batta, A.K.; Frieden, R.; Chen, T.S.; Salen, G. Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome. *N. Engl. J. Med. 1994, 330, 107–113. [CrossRef] [PubMed]

163. Thurm, A.; Tierney, E.; Farmer, C.; Albert, P.; Joseph, L.; Swedo, S.; Bianconi, S.; Bukelis, I.; Wheeler, C.; Sarphare, G.; et al. Development, behavior, and biomarker characterization of Smith-Lemli-Opitz syndrome: An update. *J. Neurodev. Disord. 2016, 8, 12. [CrossRef] [PubMed]

164. Baieli, S.; Pavone, L.; Meli, C.; Fiumara, A.; Coleman, M. Autism and phenylketonuria. *J. Autism Dev. Disord. 2003, 33, 201–204. [CrossRef] [PubMed]

165. Miladi, N.; Larnaout, A.; Kaabachi, N.; Helayem, M.; Ben Hamida, M. Phenylketonuria: An underlying etiology of autistic syndrome report. *J. Child Neurol. 1992, 7, 22–23. [CrossRef] [PubMed]

166. Fon, E.A.; Sarrazin, J.; Meunier, C.; Alarcia, J.; Shevell, M.I.; Philippe, A.; Leboyer, M.; Rouleau, G.A. Adenylosuccinate lyase (ADSL) and infantile autism: Absence of previously reported point mutation. *Am. J. Hum. Genet. 1995, 5, 554–557. [CrossRef] [PubMed]

167. Jaeken, J.; van den Bergh, G. An infantile autistic syndrome characterized by the presence of succinylpurines in body fluids. *Lancet 1984, 2, 1058–1061. [PubMed]

168. Race, V.; Marie, S.; Vincent, M.F.; van der Berghe, G. Clinical, biochemical and molecular genetic correlations in adenylosuccinate lyase deficiency. *Hum. Mol. Genet. 2000, 9, 2159–2163. [CrossRef] [PubMed]

169. Stone, R.L.; Aimi, J.; Barshop, B.A.; Jaeken, J.; van den Bergh, G.; Zalkin, H.; Dixon, J.E. A mutation in adenylosuccinate lyase associated with mental retardation autistic features. *Nat. Genet. 1992, 1, 59–63. [CrossRef] [PubMed]

170. Jinnah, H.A.; Sabina, R.L.; Van Den Bergh, G. Metabolic disorders of purine metabolism affecting the nervous system. *Handb. Clin. Neurol. 2013, 113, 1827–1836. [PubMed]

171. Nasrallah, F.; Feki, M.; Kaabachi, N. Creatine and creatine deficiency syndromes: Biochemical and clinical aspects. *Pediatr. Neurol. 2010, 42, 163–171. [CrossRef] [PubMed]

172. Faggioli, P.; Arias, A.; Vilaseca, M.A.; Ribes, A.; Artuch, R.; Sans-Fito, A.; Moreno, A.; Jakobs, C.; Salomon, G. X-linked creatine transporter deficiency in two patients with severe mental retardation and autism. *J. Inherit. Metab. Dis. 2006, 29, 220–223. [CrossRef] [PubMed]

173. Schulze, A.; Bauman, M.; Tsai, A.C.; Reynold, A.; Roberts, W.; Anagnostou, E.; Cameron, J.; Nozzolillo, A.A.; Chen, S.; Kyriakopoulou, L.; et al. Prevalence of creatine deficiency syndromes in children with nonsyndromic autism. *Pediatrics 2016. [CrossRef] [PubMed]

174. Campistol, J.; Diez-Juan, M.; Callejo, L.; Fernandez-De Miguel, A.; Casado, M.; Garcia Cazorla, A.; Lozano, R.; Artuch, R. Inborn error metabolic screening in individuals with nonsyndromic autism spectrum disorders. *Dev. Med. Child Neurol. 2016, 58, 842–847. [CrossRef] [PubMed]

175. Durand, C.M.; Betancur, C.; Boeckers, T.M.; Bockmann, J.; Chaste, P.; Fauchereau, F.; Nygren, G.; Rastam, M.; Gillberg, I.C.; Auckarsatér, H.; et al. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. *Nat. Genet. 2007, 39, 25–27. [CrossRef] [PubMed]

176. Moessner, R.; Marshall, C.R.; Sutcliffe, J.S.; Skag, J.; Pinto, D.; Vincent, J.; Zwaigenbaum, L.; Fernandez, B.; Roberts, W.; Szatmari, P.; et al. Contribution of SHANK3 mutations to autism spectrum disorder. *Am. J. Hum. Genet. 2007, 81, 1289–1297. [CrossRef] [PubMed]

177. Guilmatre, A.; Huquet, G.; Delorme, R.; Bourgeron, T. The emerging role of SHANK genes in neuropsychiatric disorders. *Dev. Neurobiol. 2014, 74, 113–122. [CrossRef] [PubMed]

178. Feng, J.; Schroer, R.; Yan, J.; Song, W.; Yang, C.; Bockholt, A.; Cook, E.H., Jr.; Skinner, C.; Schwartz, C.E.; Sommer, S.S. High frequency of neurexin 1β signal peptide structural variants in patients with autism. *Neurosci. Lett. 2006, 27, 10–13. [CrossRef] [PubMed]

179. Ching, M.S.; Shen, Y.; Tan, W.H.; Jeste, S.S.; Morrow, E.M.; Chen, X.; Mukaddes, N.M.; Yoo, S.Y.; Hanson, E.; Hundley, R.; et al. Deletions of NRXN1 (neurexin-1) predispose to a wide spectrum of developmental disorders. *Am. J. Med. Genet. 2010, 153, 937–947. [CrossRef] [PubMed]

180. Autism Genome Project Consortium. Mapping autism risk loci using genetic linkage and chromosomal rearrangements. *Nat. Genet. 2007, 39, 319–328. [CrossRef] [PubMed]

181. Viñas-Jornet, M.; Esteban-Castillo, S.; Gabau, E.; Ribas-Vidal, N.; Baena, N.; San, J.; Ruiz, A.; Coll, M.D.; Novell, R.; Guitart, M. A common cognitive, psychiatric and dysmorphic phenotype in carriers of NRXN1 deletion. *Mol. Genet. Genom. Med. 2014, 2, 512–521. [CrossRef] [PubMed]
Alarcon, M.; Abrahams, B.S.; Stone, J.L. Linkage, association, and gene-expression analyses identify CNTNAP2 as an autism-susceptibility gene. Am. J. Med. Genet. 2008, 82, 150–159. [CrossRef] [PubMed]

Werling, A.M.; Bobrowski, E.; Taurines, R.; Gundelfinger, R.; Romanos, M.; Grünblatt, E.; Walitza, S. CNTNAP2 gene in high functioning autism: No association according to family and meta-analysis approaches. J. Neural Transm. 2016, 123, 353–363. [CrossRef] [PubMed]

Murdock, J.D.; Gupta, A.R.; Sanders, S.J.; Walker, M.F.; Keeney, J.; Fernandez, T.V.; Murtha, M.T.; Anyanwu, S.; Ober, G.T.; Raubeson, M.J.; et al. No evidence for association of autism with rare heterozygous point mutations in contactin-associated protein-like 2 (CNTNAP2), or in other contactin-associated proteins or contactins. PLoS Genet. 2015, 11, e1004852. [CrossRef] [PubMed]

Bakkaloglu, B.; O’Roak, B.J.; Louvi, A.; Gupta, A.R.; Abelson, J.F.; Morgan, T.M.; Chawarska, K.; Klin, A.; Ercan-Sencicek, A.G.; Stillman, A.A.; et al. Molecular cyto genetic analysis and resequencing of contactin associated protein-like 2 in autism spectrum disorders. Am. J. Hum. Genet. 2008, 82, 165–173. [CrossRef] [PubMed]

Fernandez, T.; Morgan, T.; Davis, N.; Klin, A.; Morris, A.; Farhi, A.; Lifton, R.P.; State, M.W. Disruption of contactin 4 (CNTN4) results in developmental delay and other features of 3p deletion syndrome. Am. J. Hum. Genet. 2004, 74, 1286–1293. [CrossRef] [PubMed]

Roohi, J.; Montagna, C.; Tegay, D.H.; Palmer, L.E.; DeVincent, C.; Pomeroy, J.C.; Christian, S.L.; Nowak, N.; Hatchwell, E. Disruption of contactin 4 in three subjects with autism spectrum disorder. J. Med. Genet. 2008, 46, 176–182. [CrossRef] [PubMed]

Karayannis, T.; Au, E.; Patel, J.C.; Kruglikov, I.; Marks, S.; Delorme, R.; Héron, D.; Salomon, D.; Glessner, J.; Restituito, S.; et al. Cntnap4 differentially contributes to GABAergic and dopaminergic synaptic transmission. Nature 2014, 511, 236–240. [CrossRef] [PubMed]

Zhiling, Y.; Fujita, E.; Tanabe, Y. Mutations in the gene encoding CADM1 are associated with autism spectrum disorder. Biochem. Biophys. Res. Commun. 2008, 377, 926–929. [CrossRef] [PubMed]

Fujita, E.; Tanabe, Y.; Imhof, B.A.; Mamshi, M.Y.; Momoi, T. A complex of synaptic adhesion molecule CADM1, a molecule related to autism spectrum disorder, with MUPP1 in the cerebellum. J. Neurochem. 2012, 123, 886–894. [CrossRef] [PubMed]

Kitagishi, Y.; Minami, A.; Nakahishi, A.; Ogura, Y.; Matsuda, S. Neuron membrane trafficking and protein kinases involved in autism and ADHD. Int. J. Mol. Sci. 2015, 16, 3095–3115. [CrossRef] [PubMed]

Morrow, E.M.; Yoo, S.Y.; Flavell, S.W.; Kim, T.K.; Lin, Y.; Hill, R.S.; Mukaddes, N.M.; Balykh, S.; Gascon, G.; Hashmi, A.; et al. Identifying autism loci and genes by tracing recent shared ancestry. Science 2008, 321, 218–223. [CrossRef] [PubMed]

Jamm, S.; Quach, H.; Betancur, C.; Rastam, M.; Colineaux, C.; Gillberg, I.C.; Soederstrom, H.; Giros, B.; Leboyer, M.; Gillberg, C.; et al. Mutations of the X-linked genes encode neuroligins NLGN3 and NLGN4 are associated with autism. Nat. Genet. 2003, 34, 27–29. [CrossRef] [PubMed]

Laumonnier, F.; Bonnet-Brilhaut, F.; Gotem, M.; Blanc, R.; David, A.; Moizard, M.P.; Raynaud, M.; Ronce, N.; Lemonnier, E.; Calvas, P.; et al. X-linked mental retardation and autism are associated with a mutation in the NLGN4 gene, a member of the neuroligin family. Am. J. Hum. Genet. 2004, 74, 552–557. [CrossRef] [PubMed]

Yan, J.; Oliveira, G.; Coutinho, A.; Yang, C.; Feng, J.; Katz, C.; Sram, J.; Bockholt, A.; Jones, I.R.; Craddock, N.; et al. Analysis of the neuligin 3 and 4 genes in autism and other neuropsychiatric patients. Mol. Psychiatry 2005, 10, 329–332. [CrossRef] [PubMed]

Fisch, G.S. Is autism associated with the fragile X syndrome? Am. J. Med. Genet. 1992, 43, 47–55. [CrossRef] [PubMed]

Fisch, G.S. What is associated with the fragile X syndrome? Am. J. Med. Genet. 1993, 48, 112–121. [CrossRef] [PubMed]

Rogers, S.J.; Wehner, D.E.; Hagerman, R. The behavioral phenotype in fragile X: Symptoms of autism in very young children with fragile X syndrome, idiopathic autism, and other developmental disorders. J. Dev. Behav. Pediatr. 2001, 22, 409–417. [CrossRef] [PubMed]
223. Constantino, J.N.; Zhang, Y.; Holzhauer, K.; Sant, S.; Long, K.; Vallorani, A.; Malik, L.; Gutmann, D.H. Distribution and Within-Family specificity of quantitative autistic traits in patients with neurofibromatosis type I. *J. Pediatr.* **2015**, *167*, 621–626. [CrossRef] [PubMed]

224. Garg, S.; Plasschaert, E.; Descheemaeker, M.J.; Huson, S.; Borghgraef, M.; Vogels, A.; Evans, D.G.; Legius, E.; Green, J. Autism spectrum disorder profile in neurofibromatosis type I. *J. Autism Dev. Disord.* **2015**, *45*, 1649–1657. [CrossRef] [PubMed]

225. Plasschaert, E.; Descheemaeker, M.J.; Van Eylen, L.; Noens, I.; Steyaert, J.; Legius, E. Prevalence of autism spectrum disorder symptoms in children with neurofibromatosis type I. *Am. J. Med. Genet.* **2014**, *168*, 72–80. [CrossRef] [PubMed]

226. Timonen-Sovio, L.; Vanhala, R.; Malm, H.; Hinkka-Yli-Salomäki, S.; Gissler, M.; Brown, A.; Sourander, A. Brief report: Syndromes in autistic children in a Finnish birth cohort. *J. Autism Dev. Disord.* **2016**, *46*, 2780–2784. [CrossRef] [PubMed]

227. Sheth, K.; Di Filippo, T.; Roccella, M. Behavioral phenotype and autism spectrum disorders in Cornelia de Lange syndrome. *Ment. Illn.* **2015**, *7*, 5988. [CrossRef] [PubMed]

228. Srivastava, S.; Landy-Schmitt, C.; Clark, B.; Kline, A.D.; Specht, M.; Grados, M.A. Autism traits in children and adolescents with Cornelia de Lange syndrome. *Am. J. Med. Genet.* **2014**, *164*, 3035–3041. [CrossRef] [PubMed]

229. De Wolf, V.; Crepel, A.; Schuit, F.; van Lommel, L.; Ceulemans, B.; Steyaert, J.; Seuntjens, E.; Peeters, H.; Devriendt, K. A complex Xp11.22 deletion in a patient with syndromic autism: Exploration of *FAM120C* as a positional candidate gene for autism. *Am. J. Med. Genet.* **2014**, 164, 3035–3041. [CrossRef] [PubMed]

230. Timonen-Soivio, L.; Vanhala, R.; Malm, H.; Hinkka-Yli-Salomäki, S.; Gissler, M.; Brown, A.; Sourander, A. Brief report: Syndromes in autistic children in a Finnish birth cohort. *J. Autism Dev. Disord.* **2016**, *46*, 2780–2784. [CrossRef] [PubMed]

231. Albuquerque Retuerto, A.I.; Cantor, R.M.; Gleeson, J.G.; Ustaszewska, A.; Schackwitz, W.S.; Pennacchio, L.A.; Srivastava, S.; Landy-Schmitt, C.; Clark, B.; Kline, A.D.; Specht, M.; Grados, M.A. Autism traits in children and adolescents with Cornelia de Lange syndrome. *Am. J. Med. Genet.* **2014**, *164*, 321, 1400–1410. [CrossRef] [PubMed]

232. Alvarez Retuerto, A.I.; Cantor, R.M.; Gleeson, J.G.; Ustaszewska, A.; Schackwitz, W.S.; Pennacchio, L.A.; Geschwind, D.H. Association of common variants in the Joubert syndrome gene (*AHI1*) with autism. *Hum. Mol. Genet.* **2008**, *17*, 3887–3896. [CrossRef] [PubMed]

233. Ionita-Laza, I.; Capanu, M.; De Rubeis, S.; McCallum, K.; Buxbaum, J.D. Identification of rare causal variants in sequence-based studies: Methods and applications to *VPS13B*, a gene involved in Cohen syndrome and Autism. *PLoS Genet.* **2014**, *10*, e1004729. [CrossRef] [PubMed]

234. Howlin, P.; Karpf, J.; Turk, J. Behavioural characteristics and autistic features in individuals with Cohen syndrome. *Eur. Child Adolesc. Psychiatry* **2005**, *14*, 57–64. [CrossRef] [PubMed]

235. Chandler, K.E.; Moffett, M.; Clayton-Smith, J.; Baker, G.A. Neuropsychological assessment of a group of UK patients with Cohen syndrome. *Neuropediatrics* **2003**, *34*, 7–13. [CrossRef] [PubMed]

236. Lerma-Carrillo, I.; Molina, J.D.; Cuevas-Duran, T.; Julve-Correcher, C.; Espejo-Saavedra, J.M.; Andrade-Rosa, C.; Lopez-Muñoz, F. Psychopathology in the Lujan-Fryns syndrome: Report of two patients and review. *Am. J. Med. Genet.* **2006**, *140*, 2807–2811. [CrossRef] [PubMed]

237. Alfieri, P.; Piccini, G.; Caciolo, C.; Perrino, F.; Gambardella, M.L.; Mallardi, M.; Cesari, L.; Leoni, C.; Leone, D.; Fossati, C.; et al. Behavioral profile in RASopathies. *J. Med. Genet.* **2014**, *166*, 934–942. [CrossRef] [PubMed]

238. Adviento, B.; Corbin, L.L.; Widjaja, F.; Desachy, G.; Enrique, N.; Rosser, T.; Risi, S.; Marco, E.J.; Hendren, R.L.; Bearden, C.E.; et al. Autism traits in the RASopathies. *J. Med. Genet.* **2014**, *51*, 10–20. [CrossRef] [PubMed]

239. Ghaziuddin, M.; Bolyard, B.; Alessi, N. Autistic disorder in Noonan syndrome. *J. Intellect. Disabil. Res.* **1994**, *38*, 67–72. [CrossRef] [PubMed]

240. Johansson, M.; Wentz, E.; Fernell, E.; Strömland, K.; Miller, M.T.; Gillberg, C. Autistic spectrum disorders in Möbius sequence: a comprehensive study of 25 cases. *Dev. Med. Child Neurol.* **2001**, *43*, 338–345. [CrossRef] [PubMed]

241. Briegel, W.; Schimek, M.; Kamp-Becker, I.; Hofmann, C.; Schwab, K.O. Autism spectrum disorders in children and adolescents with Möbius sequence. *Eur. Child Adolesc. Psychiatry* **2009**, *18*, 515–519. [CrossRef] [PubMed]

242. Helmsmoortel, C.; Vulto-van Silfhout, A.T.; Coe, B.P.; Vandeweyer, G.; Rooms, L.; van den Ende, J.; Schuurs-Hoeijmakers, J.H.; Marcelis, C.L.; Willemsen, M.H.; Vissers, L.E.; et al. A SWI/SNF-related autism syndrome caused by de novo mutations in ADNP. *Nat. Genet.* **2014**, *46*, 380–384. [CrossRef] [PubMed]
243. Splawski, I.; Timothy, K.W.; Sharpe, L.M.; Decher, N.; Kumar, P.; Bloise, R.; Napolitano, C.; Schwartz, P.J.; Joseph, R.M.; Condouris, K.; et al. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. *Cell* 2004, 119, 19–31. [CrossRef] [PubMed]

244. Huguet, G.; Ey, E.; Bourgeron, T. The genetic landscapes of autism spectrum disorders. *Annu. Rev. Genom. Hum. Genet.* 2013, 14, 191–213. [CrossRef] [PubMed]

245. Schaefer, G.B. Clinical genetic aspects of autism spectrum disorders. *Int. J. Mol. Sci.* 2016, 17, 180. [CrossRef] [PubMed]

246. Lord, C.; Rutter, M.; Le Couteur, A. Autism diagnostic interview-revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. *J. Autism Dev. Disord.* 1994, 24, 659–685. [CrossRef] [PubMed]

247. Lord, C.; Risi, S.; Lambrecht, L.; Cook, E.; Leventhal, B.; DiValore, P.; Pickles, A.; Rutter, M. The autism diagnostic observation schedule-generic: A standard measures of social and communication deficits associated with the spectrum of autism. *J. Autism Dev. Disord.* 2000, 30, 205–223. [CrossRef] [PubMed]

248. Risi, S.; Lord, C.; Gotham, K.; Corsello, C.; Chrysler, C.; Szatmari, P.; Cook, E.H., Jr; Leventhal, B.L.; Pickles, A. Combining information from multiple sources in the diagnosis of autism spectrum disorders. *J. Am. Acad. Child Adolesc. Psychiatry* 2006, 45, 1094–1103. [CrossRef] [PubMed]

249. Schaefer, G.B.; Mendelson, N.J. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions. *Genet. Med.* 2013, 15, 399–407. [CrossRef] [PubMed]

250. Ponsot, O.; Moutard, M.L.; Villeneuve, N. Orientation Diagnostique en Neurologie Pédiatrique. In Neurologie Pédiatrique, 2nd ed.; Flammarion Mécadine-Sciences: Paris, France, 1998; pp. 75–87.

251. Simonoff, E.; Bolton, P.; Rutter, M. Mental retardation: Genetics findings, clinical implications and research agenda. *J. Child Psychol. Psychiatry* 1996, 37, 259–280. [CrossRef] [PubMed]

252. Hoffmann, T.J.; Windham, G.C.; Anderson, M.; Croen, L.A.; Grether, J.K.; Risch, N. Evidence of reproductive stoppage in families with autism spectrum disorder: A large, population-based cohort study. *JAMA Psychiatry* 2014, 71, 943–951. [CrossRef] [PubMed]

253. Ozonoff, S.; Young, G.S.; Carter, A.; Messinger, D.; Yirmiya, N.; Zwaigenbaum, L.; Bryson, S.; Carver, L.J.; Constantino, J.N.; Dobkins, K.; et al. Recurrence risk for autism spectrum disorders: A baby siblings research consortium study. *Pediatrics* 2011, 128, 488–495. [CrossRef] [PubMed]

254. Durkin, M.S.; Maenner, M.J.; Newschaffer, C.J.; Lee, L.C.; Cunniff, C.M.; Daniels, J.L.; Kirby, R.S.; Leavitt, L.; Miller, L.; Zahorodny, W.; et al. Advanced parental age and the risk of autism spectrum disorder. *Am. J. Epidemiol.* 2008, 168, 1268–1276. [CrossRef] [PubMed]

255. Lord, C. Diagnostic Instruments in Autism Spectrum Disorders. In *Handbook of Autism and Pervasive Developmental Disorders*, 2nd ed.; Cohen, D.J., Volkmar, F.R., Eds.; John, Wiley and Sons Inc.: New York, NY, USA, 1997; pp. 460–483.

256. Anastasi, A. *Psychological Testing*, 6th ed.; Macmillan Publishing Co Inc.: New York, NY, USA, 1988.

257. *Manual for the Raven’s Color Progressive Matrices (CPM)*; Les Editions Centre de Psychologie Appliquée (ECPA): Paris, France, 2016.

258. Guinchat, V.; Thorsen, P.; Laurent, C.; Cans, C.; Bodeau, N.; Cohen, D. Pre-peri-and neonatal risk factors for autism. *Acta Obstet. Gynecol. Scand.* 2012, 91, 287–300. [CrossRef] [PubMed]

259. Gardener, H.; Spiegelman, D.; Buka, S.L. Perinatal and neonatal risk factors for autism: A comprehensive meta-analysis. *Pediatrics* 2011, 128, 344–355. [CrossRef] [PubMed]

260. Weissman, J.R.; Kelley, R.I.; Bauman, M.L.; Cohen, B.H.; Murray, K.F.; Mitchell, R.L.; Kern, R.L.; Natowicz, M.R. Mitochondrial disease in autism spectrum disorder patients: A cohort analysis. *PLoS ONE* 2008, 3, e3815. [CrossRef] [PubMed]

261. Rossignol, D.A.; Frye, R.E. Mitochondrial dysfunction in autism spectrum disorders: A systematic review and meta-analysis. *Mol. Psychiatry* 2012, 17, 290–314. [CrossRef] [PubMed]

262. Demily, C.; Assouline, M.; Boddart, N.; Barcia, G.; Besmond, C.; Poisson, A.; Sanlaville, D.; Munnich, A. Genetic approaches in autism spectrum disorders. *Neuropsychiatr. Enfance Adolesc.* 2016, 64, 395–401. [CrossRef]

263. Lai, M.C.; Lombardo, M.V.; Baron-Cohen, S. Autism. *Lancet* 2014, 383, 896–910. [CrossRef]
264. Tordjman, S.; Anderson, G.M.; Bellissant, E.; Botbol, M.; Charbuy, H.; Camus, F.; Graignic, R.; Kermarrec, S.; Fougerou, C.; Cohen, D.; et al. Day and nighttime excretion of 6-sulphatoxymelatonin in adolescents and young adults with autistic disorder. *Psychoneuroendocrinology* 2012, 37, 1990–1997. [CrossRef] [PubMed]

265. Haag, G.; Tordjman, S.; Duprat, A.; Urwand, S.; Jardin, F.; Clement, M.C.; Cukierman, A.; Druon, C.; Maufras du Chatellier, A.; et al. Presentation of a diagnostic grid of the progressive stages of infantile autism as observed in treatment. *Int. J. Psychoanal.* 2005, 86, 335–352. [CrossRef] [PubMed]

© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).